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Global incidence rates for tuberculosis (TB) indicate a gender-bias to the disease, with almost twice as 
many men actively infected than women (male/female ratio of 1.9). Sex hormones are known to regulate 
immune function and their role in tuberculosis has been suggested experimentally in animal models. 
However the role of sex hormones in human TB infection and whether there is any synergistic effect in 
HIV and TB co-infection is unknown. In addition, there is data to suggest that manipulation of sex hormones 
with progestin-based injectable contraceptives, particularly DMPA, increases susceptibility to both HIV 
and TB. Quantitation of sex hormones has relied on antibody based immunoassays, such as ELISA, which 
suffer both from a lack of specificity and sensitivity.  
Aims: 
Consequently, the purpose of this study was to develop a method for quantitation of sex hormones and their 
contraceptive analogues utilizing a targeted LC-MS/MS approach that has been demonstrated to increase 
the accuracy of hormone quantitation and to determine the effect of sex hormones and hormonal 
contraceptives on the immune response to TB and HIV. 
Method: 
Sex hormone levels were measured in plasma samples from three separate cohorts, using MRM run in 
positive ESI mode, on a ABSciEx Q-TRAP 5500 mass spectrometer. The method was validated and DMPA 
levels were measured in the FRESH cohort (n= 62) and CAPRISA CAP004 study (n= 38) to determine 
effects on DMPA on increased risk in HIV acquisition. Testosterone, progesterone and DMPA levels were 
measured in the HIV chronic patients from the Cryptococcal cohort (n = 271) and sex hormone associated 
changes in phenotypic expression and immunological responses using intracellular cytokine staining were 
determined by flow cytometry analysis. 
Results: 
We validated our assays and were able to identify and quantitate levels of DMPA in two blinded studies. 
In the FRESH cohort, we were able to correctly identify and quantitate DMPA levels in Depo-Provera users 
and injectable progestin-based (IPC) contraceptive use was associated with high risk of HIV acquisition (p 
= 0.0142). IPC users were found to have significant increase in CCR5+CD4+ T cells in the cervix as well 
as increased CCR5 expression. Preliminary data in the CAP004 study, showed differential expression of 




In the Cryptococcal study, we found, as expected, significant differences in testosterone and progesterone 
levels between male and female patients, p <0.0001 and p=0.0001 respectively. Given that only 3 female 
patients reported to be using the contraceptive DMPA, we identified 42 of the total number of 172 females 
to have significant levels of DMPA (greater than LOQ = 0.064ng/ml) and these females had significantly 
lower progesterone levels than females not using DMPA (p <0.0001). This large under-reporting of 
contraceptive use indicates the value in direct measurement as opposed to self-reporting. As expected 
negative correlation was observed between progesterone and DMPA levels (p = 0.0016, r = -0.2445). 
However, individual response profiles are highly variable and decay rates of DMPA in longitudinal samples 
vary greatly between individuals. We hypothesis this will impact the immunomodulatory effect of DMPA, 
again suggesting the need for direct measurement.   
In this small sample we find no significant differences in activation and exhaustion of CD4 and CD8 T cells 
(determined using HLA-DR, CD38 and PD1 expression), as well as T regulatory cells (FoxP3 expression) 
when comparing female patients with high progesterone, low progesterone, and injectable contraceptive 
DMPA users, as well as males with high testosterone and low testosterone levels. However, females with 
high progesterone levels generally had higher CD38 expression, though non-significant. Also, we observe 
no significant differences in cytokine expression (TNFα, IFNγ, and IL-2) as well as markers, CD107a and 
Mip-1β, upon stimulation with SEB, PPD, pp65 CMV and HIV peptides. 
Conclusion: 
We successfully optimized and validated a method for quantitation of sex hormones using LC-MS/MS and 
were able to detect and quantify levels of testosterone, progesterone and DMPA. This method has the 
potential in clinical studies, to eliminate the need to rely on self-reported information, as exogenous 
hormones or contraceptive analogues can be detected with high sensitivity and specificity. Changes in the 
female genital tract which may be associated with increased risk of HIV were found in injectable progestin-
based contraceptive users, particularly DMPA. However, no significant immunological effects of hormone 




1. TUBERCULOSIS INTRODUCTION 
 
1.1 TB EPIDEMIOLOGY 
Tuberculosis (TB) is ranked alongside human immunodeficiency virus (HIV), as a leading cause of death 
due to an infectious disease. Despite all the various strategies being implemented to reduce and eliminate 
this serious threat to global human health, the World Health Organizations’ Report of 2015 estimates that 
in 2014, 9.6 million people developed TB, and that approximately 1.5 million died from the disease (Figure 
1.1 ) [1]. 
 
Figure 1.1. Estimated TB incidence rates per country in 2014. The map shows incident cases of TB per 
100 000 population, with emphasis on the labeled countries as the ‘high burden countries’ (HBCs). Adapted 






Of the estimated cases of people who developed TB, a quarter of the cases occur in the African region, 
which has the highest rates of incidence and deaths relative to population [1]. TB disease control is 
complicated by co-infection with HIV, which exacerbates disease incidence and severity.  The sub-Saharan 
African region in particular, has highest incident rates due, in part, to high prevalence of HIV. HIV infected 
patients are 26 times more likely to present with TB and approximately 1.15 (12%) million cases of active 
TB in 2014 were HIV positive [1]. 
 
Although millions of incident cases of TB are reported annually, a large proportion of infected people 
effectively contain the bacteria and are said to have “latent” M. tuberculosis infection (LTBI) [2]. These 
people remain asymptomatic and do not show any clinical evidence of the disease. Approximately a third 
of the world population is estimated to have LTBI, and, in the absence of co-morbidities such as HIV, this 
group carries a 5-10% lifetime risk of reactivating the infection to active TB. Reactivation rate in the 
presence of HIV co-infection is increased by 20 to 37-fold, depending on severity of the epidemic [3]. 
Therefore, this means that nearly 2 billion LTBI individuals have a huge potential to develop active disease 
[2] (Figure 1.2). 
 
1.2 TB PATHOLOGY 
Tuberculosis, caused by the tubercle bacillus Mycobacterium tuberculosis, is predominantly an infection 
of the lung, although M. tuberculosis can disseminate to other organs including the lymph nodes, bone and 
meninges causing extra pulmonary disease [4]. Transmission of the bacillus is airborne, spread by 
individuals with active pulmonary tuberculosis mainly through inhalation of aerosolized bacilli. 
The ability to develop an infection depends on susceptibility of host, environmental conditions, number of 
bacilli and size of droplets, degree of ventilation, frequency and duration of exposure, amongst other factors 
[5]. Only a small fraction, about five percent of the primary infections develop into clinically apparent 








Figure 1.2. The epidemiology of M. tuberculosis infection—active and latent TB. Adapted from O’Garra 
et al. 2013 [4]. 
 
Host factors that lead to containment of infection (LTBI) or progression to active disease are not fully 
understood. However it is thought that a balance between the pro-inflammatory and anti-inflammatory 
immune responses is crucial to controlling infection.  
Early after inhalation of M.tuberculosis, bacilli are phagocytosed by alveolar macrophages and dendritic 
cells (DCs) in the alveolar space. This process is mediated by several host cell receptors expressed on 
phagocytic cells, which include pathogen recognition receptors (PRRs) such as macrophage mannose 
receptors and some members of the toll-like receptor (TLR) family. These PRRs recognize pathogen-
associated molecular patterns (PAMPs) present on bacterial surface [2, 5]. Macrophages then migrate to 
the lung parenchyma, where both innate and adaptive immune responses are initiated. Intracellular 
M.tuberculosis induces production of high levels of pro-inflammatory cytokines and chemokines such as 
TNF-α, IL-12, IL-6 and IL-1β by macrophages [2]. 
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This process drives the recruitment of uninfected macrophages and other cells such as neutrophils, 
monocytes and DCs from circulation into the lung where they begin to phagocytose the bacteria. Bacterial 
growth is arrested in infected macrophages due to delayed-type hypersensitivity (DTH) and the recruited 
innate immune cells begin formation of an early granuloma [4, 6]. Infected DCs in the lung migrate into 
the lung-draining lymph nodes (LDLN), where they present mycobacterial antigens to lymphocytes. 
This process primes the adaptive immune system for a systemic response, and does not occur until about 
12-21 days post-infection in TB, significantly delayed compared with other infections [7] (Figure 1.3). Mice 
aerosol infection studies suggest that the delayed priming of effector CD4+ and CD8+ T cells may be due 
to the fact that M.tb antigens must be transported to the LDLN for antigen presentation to occur. This delay 
could allow dissemination of bacteria before M.tb-specific T cells are activated [8, 9]. 
 
Figure 1.3. Adaptive immune response in Mycobacterium tuberculosis infection is significantly delayed 
compared with other infections. In acute, resolving infections, initiation of T-cell responses occurs 3 – 5 
days after initial infection whereas aerosol infection with M. tuberculosis, only 9 – 11 days after infection 
and peak more than a few weeks after infection, without elimination of M.tb bacilli. Adapted from Urdahl 
et al, 2011 [7]. 
 
The most common outcome of TB infection is the formation of granuloma – a hallmark pathology structure 
of TB. Onset of cell-mediated immunity results in a well-developed granuloma or stabilized caseous lesion, 
which is mainly composed of central, infected macrophages, surrounded by epithelial macrophages, 
dendritic cells, neutrophils, foam cells, giant Langhan type cells, peripheral recruited T and B lymphocytes 
and sometimes fibroblasts [10]. 
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The granuloma functions as both a niche in which the bacillus can grow or persist and an immunologic 
environment in which immune host cells interact to control and prevent dissemination of infection [2]. In 
LTBI cases, the full extent of what latency means is not yet understood; the microbiologic state of the bacilli 
is not clear, since they may be in a truly latent state or in a state of persistent anaerobic metabolic non latent 
state. Alternatively, they may be in a state of intermittent dormancy and replication [11]. Most hosts usually 
have one or few granulomas and are capable of limiting the growth and spread of the bacteria. Failure to 
control the infection, as is the case with active TB, is associated with development of caseating granulomas 
leading to spread of M.tuberculosis throughout the lung or dissemination to other organs and initiating new 
granuloma formation [2].  
 
Figure 1.4. TB pathogenesis. Balance in pathogen-host interactions during M.tb infection can lead to (i) 
infection elimination, (ii) failure of host to control infection, leading to active TB, and (iii) containment of 
M.tb in LTBI individuals, with 5-10% risk of reactivation to active TB. Adapted from Kauffman & 
McMichael, 2005 [12].  
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For infection of a new host to occur, M.tb must exit the granuloma into the airway where they can be 
aerosolized into cough droplets. Studies suggest that cavity formation in the granuloma results from necrotic 
death of infected macrophages, leading to extracellular replication of the bacteria. Granuloma dynamics 
that favour necrosis are not fully understood but it is thought that M.tb manipulates host response factors, 
such as TNF, to exit granuloma for transmission [13]. Most important in cavity formation, is liquefaction 
of the solid caseum which then provides a permissive environment in which M.tb replicates. [14].The semi-
liquid necrotic material spreads across the bronchi, where it can be easily coughed up, leading to 
transmission, or infect new macrophages to create more lesions.         
 
1.3 TB VACCINES, TREATMENT AND OUTCOMES 
 
1.3.1 TB vaccines 
For nearly a century, an attenuated Mycobacterium bovis, bacillus Calmette-Guerin (BCG) vaccine has 
been used as a preventive measure for TB. However, there have been questions raised on the effectiveness 
of the vaccine due to variations in the protective effect of BCG in different populations. Though it provides 
some protection in infants, particularly from miliary TB, the efficacy, however, diminishes over a period 
of 10-15 years and does not provide protection against pulmonary TB in adults [15, 16].  
 
A systematic review and meta-analysis study by Abubakar et al, concluded that latitude, age at which 
vaccine is given and the pre-vaccination tuberculin sensitivity status were some of the factors considered 
to contribute to the observed variation in BCG induced protection [15]. In fact, in one mouse study, 
sensitization with mycobacterial isolates from soil and sputum impaired the development of protective 
immunity to TB upon subsequent vaccination with BCG, suggesting that preexisting immunity to 
environmental mycobacteria could prevent multiplication of vaccine BCG and probably contributes to the 
limited induction of protective responses in some regions [17].  Given the very high mortality and morbidity 
rates in countries where most infants are vaccinated with BCG, an alternate vaccine is needed, that will 





1.3.2 TB drug therapy 
The current standard TB treatment for drug susceptible TB is a 6-month regimen that comprises of an initial 
intensive phase therapy of four drugs namely isoniazid, rifampicin, ethambutol and pyrazinamide given for 
2 months. This is followed by a continuation phase of isoniazid and rifampicin, usually lasting 4-6 months 
[1]. There may be variations to this treatment depending on diagnostic category of each patient. For 
example, new smear positive patients, previously treated smear positive or relapse patients, treatment 
interrupted or treatment failure patients, may be treated differently [18]. 
 
WHO reports treatment success rate of approximately 85% or more in newly reported cases of TB. However 
treatment for multi-drug resistant TB (MDR-TB), defined by resistance to the two first-line TB drugs, 
isoniazid and rifampicin, has lower success rates and therapy lasts longer, approximately 20 months (1).  
This necessitates the need for effective interventions that are able to either prevent infections (e.g. effective 
vaccines) or shorten treatment as well as target MDR-TB and XDR-TB strains effectively.  
 
1.3.3 Host-directed TB therapy 
Recently, there has been a new focus investigating alternate interventions that target host immune responses 
to TB infection, rather than targeting the bacteria themselves, a concept known as host-directed therapies 
(HDT) [19, 20]. This concept could be used to improve treatment efficacy and outcomes, for better control 
of drug-resistant strains and reduce severity of infection, as well as mortality. The host provides a wide 
range of molecular pathways and inhibitory small molecules that could be potential targets for HDT, from 
mechanisms involved in macrophage function such as lipid metabolism, eicosanoids and cell death, 
phagosome acidification, to cytokine modulation and tissue homeostasis, to mention a few. [21] For 
example, a proof of concept study by Mayer-Barber et al 2014, showed that induction of eicosanoid, 
prostaglandin E2 (PGE2) through interleukin-1 (IL-1), limited production of excessive type-1 interferon 
(IFN), known to promote disease exacerbation [22]. 
These strategies demonstrate that manipulation of host mechanisms represent feasible therapies that could 
be used in conjunction with, or alternative to conventional chemotherapy. Understanding the function of 
immune responses, and how these could be exploited with HDT, could inform more target situations such 
as sex-based differences in immune responses and susceptibility to TB observed in men, compared to 
women, which will be described later, in chapter 3.  
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2.0 TUBERCULOSIS AND HIV CO-INFECTION 
 
2.1 TB/HIV EPIDEMIOLOGY 
Emergence of HIV/AIDS pandemic in the 1980s led to a major upsurge in TB cases and TB mortality. 
Today, HIV is the most prevailing known risk factor predisposing for M.tuberculosis infection and 
progression to active disease. WHO estimates that 12% of people who developed TB worldwide were HIV 
positive and 78% of which were in the African region [1]. The greatest burden of TB and HIV co-infection 
is observed in the sub-Saharan Africa, where the enormous size of the problem is tragically, inversely 
proportionate to the paucity of resources available for its control [23]. The risk for LTBI reactivation is 
approximately 20-fold more in HIV-infected people [24]. 
 
 
Figure 2.1. Estimated HIV prevalence in new and relapse cases of TB in 2014. Map shows percentage 





2.2 TB/HIV PATHOLOGY 
In TB and HIV co-infection, M.tuberculosis and HIV act in synergy, accelerating the decline of 
immunological functions [24]. HIV causes a generalized depletion of CD4+ T-cells, a subset of T-cells 
known to be important in the control of TB infection. Additionally, it has been suggested that HIV-1 may 
preferentially infect and deplete M.tb-specific CD4+ T cells [25], therefore causing direct impairment of 
M.tb immune control. Treatment with highly active anti-retro viral therapy (HAART) restores these M.tb-
specific CD4+ T cells leading to improved immune responses [26]. HIV has effects on other cells, including 
macrophages, and influences production of cytokines such as TNF-α, important in containing an initial M.tb 
infection. 
Studies suggest that the increase in pathology associated with TB and HIV co-infection is caused by 
functional disruption of the local immune response within both established and newly forming granulomas 
[27]. This likely causes a decrease in the ability of granulomas to contain M.tuberculosis infection, leading 
to increased bacterial growth, more dissemination and eventually, severe pathology (Figure 1.6). 
 
Figure 2.2. Proposed mechanism of HIV-induced reactivation of latent TB. HIV entry induces functional 
disruption and dissemination of granuloma leading to either a) continued M.tb dissemination and early TB 
reactivation or, b) temporary control in fibrotic granuloma, and prevents reactivation. Adapted from 





2.3 HIV/TB TREATMENT OUTCOMES 
The number of people dying from HIV-associated TB has been falling globally since 2002, as a result of 
antiretroviral therapy (ART) treatment in notified cases of TB associated with HIV infection [1]. WHO 
estimates that ART reduces the individual risk of TB disease among people living with HIV by 65% [1]. 
Initiation of ART results in sudden restoration of immune responses, accompanied by increase in CD4 T 
cell count and rapid decrease in viral load [28].  
 
However, despite early initiation of ART, mortality in patients with TB/HIV co-infection, especially in 
developing countries, remains high in the first 3 months after initiation of highly active ART (HAART), in 
large part, as a result of a paradoxical reaction called immune reconstitution inflammatory syndrome (IRIS), 
or TB-IRIS in case of TB infection [28]. In these cases, the recovering immune system reacts to the high 
bacterial burden present, resulting in an uncontrolled and excessive immune response, termed a cytokine 
storm, leading to organ damage and death in the most extreme cases. Other complications that may result 
from concurrent treatment of both TB and HIV include drug-drug interactions and, poor patient adherence 



















It has long been known that the incidence and severity of infectious diseases due to bacteria, parasites and 
viruses, are different between males and females, in both humans and a variety of other species [30]. In 
general, both the proportion of individuals infected and the severity of infection are higher in males than 
females [31]. For instance, gender disparities in favour of males are observed in most parasitic infections 
including schistosomiasis, leishmaniasis and malaria [reviewed in 32 & 33]. A study by Kadioglu et.al, 
showed that in mice infected with Streptococcus pneumoniae, male mice had increased susceptibility to 
infection and had significantly lower survival rates than their female counterparts [34]. 
A recent epidemiological meta-analysis study of infectious diseases in Brazil, attempted to address the 
hypothesis that sex-based differences may be due to, either physiological effects where genetic 
(chromosomal) differences and sex hormones explain the observed sex-bias in infectious diseases. On the 
other hand, the behavioral effects hypothesis proposes that exposure arising from differences in behavior 
renders one sex more exposed than the other to certain pathogens [35]. This study, carried across in different 
age groups, revealed a post-pubertal male bias in the incidence of cutaneous and visceral leishmaniasis, 
pulmonary tuberculosis (TB), lepromatous leprosy, and leptospirosis amongst others. However in some 
diseases such as typhoid fever, there was no sex-bias [35]. The most striking observation was that male bias 
in infectious disease susceptibility could also be observed in the first year of life, when behavior is unbiased, 
but sex hormone levels transiently rise [35]. 
A recent systems analysis of response to an influenza vaccine, showed that females generally had increased 
antibody responses and inflammatory cytokines and that a cluster of genes up-regulated by testosterone 
were correlated with poor virus-neutralizing response in male [36]. Increased levels of testosterone 
inversely correlated with antibody response [36], suggesting a role for sex differences in response to 
vaccination, likely modulated by sex hormones.  
Animal model studies, which are free from confounding factors such as differences in exposure and access 
to treatment facilities, support the idea that biological mechanisms may drive the observed sex-bias in 
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infectious diseases. Also, the observation that incidence of autoimmune diseases is sex-biased towards 
females also provides insights on why these differences may be due to physiological mechanisms. Females 
are known to generally have more robust immune responses, and this sexual dimorphism in immune 
responsiveness is most accentuated post-puberty, suggesting that sex hormones play a critical role [30]. 
 
3.2 SEX-BASED DIFFERENCES IN TUBERCULOSIS 
Tuberculosis incidence and severity also shows gender-based differences (Figure 3.1). The global TB 
epidemic is characterized by significant differences in prevalence between men and women. In 2014, the 
worldwide case notification rate of TB indicated a male: female ratio of 1.7, meaning that, generally, almost 
twice as many men were diagnosed with active TB compared to women, an observation seen in the past 
years as well [1, 37]. In high burden countries (HBCs), this ratio varied from 0.7 in Afghanistan to 3.0 in 
Viet Nam, which may be indicative of real epidemiological differences between regions [1]. The male: 
female ratio for bacteriologically-confirmed TB among adults is typically around 2–3 in Asian countries 
and 1–2 in Africa, and the ratio of prevalent to notified cases is systematically higher among men than 
women [1]. It is unclear why more men than women, are diagnosed with TB. 
 
3.2.1 BEHAVIORAL EFFECTS 
Whether these observed disparities are due to behavioral or biological effects, or both, is not fully known. 
There are some compelling arguments that socio –economic and –cultural factors may play a role in TB 
gender-bias [38]. For example, males are more likely to engage in risky activities that may increase the 
likelihood of contact with the pathogen and therefore are risk factors of TB transmission, such as cigarette 
smoking and alcohol consumption. In developing countries, working in mines is regarded as a risk factor 
for tuberculosis, a profession mostly carried by men [39]. However, household contact is an even stronger 










Figure 3.1. Sex distribution of new smear-positive TB cases, showing gender inequality in TB case 
notifications globally in 2007. Adapted from Neyrolles & Quintana-Murci, 2009 [37]. 
 
The strongest risk factor for tuberculosis is co-infection with HIV. Although approximately half of HIV-
infected people globally are women, in sub-Saharan Africa this raises to 60%, and in South Africa >70% 
aged 20–30 years are women. Despite the high prevalence of HIV infection among South African women 
in this age group, however, incidence of tuberculosis remains higher in men [39]. Also, globally, mortality 
due to TB is generally higher in men in both HIV negative and positive cases, and the sex ratio varies in 
the different regions in the world (Figure 3.2). In 2014, amongst HIV-infected individuals, approximately 
890 000 men died of TB compared to 490 000 females [1]. 
 
Some reports suggest that differences in help-seeking behavior and differential access to health care 
services may result in the possibility of under notification of women, particularly in developing countries. 
The case notification rate therefore may not reveal the many facets of inequality between male and female 
patients. However, a meta-analysis study by Borgdoff et al, showed that in prevalence surveys conducted 
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in 14 countries around the world, the number of TB cases were greater in men than in women in almost all 
cases [40]. Even though there were some limitations in the data from some of the studied countries, the sex 
bias was generally observed in suggesting that sex bias in TB prevalence may represent real epidemiological 
differences [40]. 
 
In a house-to-house survey done in Bangladesh, >260,000 individuals were recruited for detection of 
suspect TB cases, followed by confirmation with smear positivity. Despite nearly equal participation 
between males and females (51% males), an excess of cases in males was observed (ratio of 3:1), even 
when confounding factors such as income, awareness and stigma were taken into account [41]. These 
differences between sexes in active TB are real, however several potential confounding factors like 
smoking, drug use, and air pollution exposure were not adjusted in their study. 
 
Figure 3.2.  Global and regional male: female ratios of death due to TB among adults aged ≥ 15 years. 
Adapted from WHO Tuberculosis Report 2015 [1]. 
 
Taken together, although there is strong support in the literature for the role for behavioral or 
epidemiological factors in TB risk, it is highly likely that the sexual dimorphism observed in TB is explained 






3.2.2 PHYSIOLOGICAL MECHANISMS 
Differences in physiological mechanisms, more specifically, sex-specific biological characteristics such as 
sex steroid hormones, genetic makeup of sex chromosomes and sex-specific metabolic features may 
account for the increased susceptibility to TB in men [37]. The study in Brazil, observed a post-pubertal 
male bias in pulmonary tuberculosis (ratio 1.9:1). Interestingly a stronger male bias was also seen in 
lepromatous leprosy (2.94:1) whereas mild tuberculous leprosy was female-biased [35]. Tuberculosis and 
leprosy have similar immuno-pathogenesis, with lepromatous disease being analogous to active 
tuberculosis and tuberculous leprosy representing cured or contained disease [39]. Crucially, both diseases 
are caused by the same pathogen, and thus male bias for the tuberculosis-like lepromatous disease is highly 
unlikely to result from differences in exposure [39]. It is worth noting that in the same study, male bias in 
these diseases was also observed in children ≤ 1 year of age. It has also been reported elsewhere, that 
primary TB infection in children under the age 2 and adolescents (≥10 years), frequently progressed to 
serious disease, whereas between the ages 2-10 years, infection rarely progressed to disease [42]. A 
common characteristic between infancy and adolescence, is a rise in sex hormone levels. 
 
3.2.2.1 Sex hormones 
Differences in sex steroid hormones have been suggested as one of the factors contributing to the male-
biased susceptibility to TB. Under controlled laboratory conditions using animal models, a clear sex-bias 
in the susceptibility of males and females can be observed, supporting the argument that TB disease could 
be influenced by sex hormones. 
Early studies in mice infected with M.marinum, a mycobacterial pathogen related to tuberculosis, showed 
higher susceptibility in males than females in terms of mortality, lesions and bacterial load in lungs and 
spleen [43]. Castration, in male mice improved their resistance, an effect substantially reversed by 
testosterone replacement. Testosterone treatment of female mice also increased their susceptibility to this 
infection, suggesting a role of the male sex hormone in reduced resistance to mycobacterial infections [43]. 
A more recent study showed similar results with M.tuberculosis infection, with female mice and castrated 
males having increased inflammation in the lung indicating better control of infection [44], whereas 
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ovariectomized female mice showed increased susceptibility to M.avium, an effect improved by estradiol 
therapy [45]. In addition, Depo Provera (depot medroxyprogesterone acetate or DMPA), a synthetic 
progesterone-based injectable contraceptive has been shown to impair M. tuberculosis infection control in 
mice [46], suggesting that hormonal contraceptives may play a role in TB risk. 
In human, early observational studies also suggest sex hormones as a predisposing factor in TB incidence 
and mortality. A Swedish study showed an increase in death of oophorectomized females (7%), in 
comparison to TB mortality rates of 0.7% in the country [47]. Also, another study in a mental institution in 
America found that medically castrated males had better survival (only 8.1% died), compared with intact 
males (20.6% died). In addition, less intact females died from tuberculosis, compared with intact males 
(15.8%) [48]. 
Such studies have prompted investigation into the ability of sex-associated hormones to influence the 
immune system. It is now widely accepted that sex hormones, directly influence the immune system. Many 
types of immune cells, including T cells, B cells, dendritic cells (DCs), macrophages, neutrophils and 
natural killer (NK) cells, express cognate intracellular receptors which suggests that sex steroid hormones 
might have a role in the regulation of immunity [31]. Mechanisms of how sex- steroid hormones interact 
with the host immune responses are not yet fully known. However, given that the sex differences observed 
in animal model studies are similar to those reported by humans, the role of sex steroids in TB and on 
underlying immune responses need to be investigated. 
 
Estradiol (17-β estradiol) 
As a general rule, females exhibit more robust cell-mediated and humoral immune responses to antigenic 
challenges, such as infection and vaccination, compared with males [31]. Data from experimental mice 
studies suggest that, 17-β estradiol, the major female sex hormone, is the driving factor behind the enhanced 
immune responses in females. A T helper-1 (Th-1) cell mediated immune response, characterized by 
production of IFN-γ and TNF-α, in particular is crucial to control of TB infection [39]. Increased levels of 
these typical CD4+ T cell cytokines, together with IL-12 and IL-17 are observed in female and castrated 
male that show less susceptibility to TB infection, compared to non-castrated males, at least during the first 
month of infection [44]. Also, 17-β estradiol significantly increases activity of the IFN-gamma promoter in 




In macrophages, 17-β estradiol is thought to enhance activation. Treatment of ovariectomized female mice 
with either placebo or 17-β estradiol for 4 weeks, showed that macrophages from mice treated with 17-β 
estradiol had markedly increased expression of pro-inflammatory cytokines, IL-1β, IL-6, and IL-12p40 and 
inducible NO synthase when stimulated ex vivo with LPS [50], probably mediated through the estrogen 
alpha receptor (ERα) expressed in these macrophages [51].  
The role of neutrophils in the pathogenesis of TB infection is poorly understood, even though they have 
been shown to be the dominant infected cell type during pulmonary TB infection [52]. A study by Berry et 
al., revealed a neutrophil driven type-1 IFN signature in patients with TB infection [53], also suggesting an 
important role for neutrophils in TB. At high levels of circulating 17 beta-estradiol, during the follicular 
phase of the menstrual cycle, neutrophils produce high levels of nitric oxide synthase, an effect also 
observed in post-menopausal women after estrogen therapy [54]. The impact of this on the control of M.tb 
is yet to be established. 
 
Testosterone 
Animal model studies suggest an immunosuppressive role for testosterone in TB infection. In general, and 
in contrast to 17-β estradiol testosterone is thought to downregulate the T helper-1 (Th) - mediated immune 
response, and in the mouse model, TB infected male mice show increased expression of these cytokines 
upon castration [44]. Also, deprivation of androgens increases absolute numbers of T cells residing in 
peripheral lymphoid tissue in mice [55]. The role played by testosterone in regulating T cell function, and 
in relation to TB infection in humans, however remains to be investigated.  
In tuberculosis, classically activated macrophages (CAMs) are induced by Th-1 signals and produce pro-
inflammatory cytokines (TNF and IL-12), and chemokines. CAMs express inducible nitric oxide synthase 
(iNOS), responsible for production of nitric oxide that can kill M.tuberculosis [2]. However, again in 
contrast to 17-β estradiol, testosterone downregulates classical activation of macrophages by inhibiting 
TLR4 expression and oxygen radical formation [56]. 
 
Progesterone  
Progesterone, a pregnancy-associated sex steroid hormone is generally known to be immunosuppressive. 
Downregulation of macrophage activity has been reported, where progesterone inhibits iNOS, activation 
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of nuclear factor-kappa B (NF-κB) and TLR4 expression, while up-regulating expression of suppressor of 
cytokine signaling (SOCS1) in LPS-stimulated macrophages [57], all of which have been reported to play 
key roles in M.tuberculosis infection control in vivo and ex vivo. The relevance to mycobacterial control is 
perhaps also illustrated by the fact that M.tb can modulate the host eicosanoid and prostaglandin metabolism 
as a survival strategy [58]. The relative levels of prostaglandin E2 (PGE2) and lipoxin A4 (LXA4) govern 
whether macrophages undergo apoptosis, a phenomenon that correlates with pathogen containment; or 
necrosis, whereby M. tuberculosis is released from the infected cell, correlating with the spread of infection 
[58]. Progesterone may play a role in this balance as it increases PGE2 production monocytes [59]. The 
effect this will have on M.tuberculosis control or spread has yet to be studied. 
  
 
Figure 3.3. Proposed mechanisms by which sex hormones modulate immune responses to M.tuberculosis 







3.2.2.2 Sex chromosomes 
Differences in disease susceptibility observed in men and women can be attributed, at least in part, to the 
bias in the X chromosome. The X chromosome encodes approximately 1100 genes, the majority of which 
are immune-related whilst the Y chromosome encodes just a fewer than a 100 genes [31]. Mutations and/or 
polymorphisms of immune-related genes encoded by the X chromosome may be important determinants of 
sex-biased immune responses [31]. Women express XX, while men express the XY genotype. Therefore, 
deleterious recessive alleles in X-linked genes (e.g., TLR7, FOXP3, CD40L, and IRAK1) are more likely 
to cause immune phenotypes in males due to the heterogametic nature of their chromosomes [31]. 
A recent study on a Chinese population examined whether the X-linked single-nucleotide polymorphisms 
(SNPs) of the TLR8, CD40LG and IRAK1 genes were associated with presentation of pulmonary 
tuberculosis. The CD40LG variant alone, and in combination with the TLR8 and IRAK1 SNPs were 
associated with increased risk of pulmonary tuberculosis in males [60]. TLR8 polymorphisms have been 
linked with susceptibility to tuberculosis in other previous studies [37, 61]. IRAK1 proteins have critical 
roles in pathogen recognition and initiation of a pro-inflammatory immune response, resulting in type I IFN 
production and induction of the IFN-inducible genes [31]. Suggesting that polymorphisms of this gene may 
lead to an impaired IFN-γ driven Th-1 type response in tuberculosis infection. 
Also, a possible role of the X chromosome in susceptibility to TB has been noted in studies of Mendelian 
susceptibility to mycobacterial diseases (MSMD), where two mutations in an X-linked gene have been 
identified in patients suffering from MSMD, some of whom also have presented TB [37]. These studies 
suggest that variation in the X chromosome may be involved in the genetic predisposition to TB, however, 
further research needs to be done with larger and well-controlled TB cohorts. 
 
3.3 SEX HORMONES AND HIV RISK 
Generally, risk of HIV acquisition is higher in females than males. More females globally, are HIV-infected 
and studies suggest a hormonal component to this observation. 17-β estradiol and progesterone levels in 
females fluctuate throughout the menstrual cycle.  Hormonal control of the innate and adaptive immune 
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systems is supported by the fact that immune protection ,in general, is reduced during the secretory phase 
of the cycle to optimize conditions for tolerance of paternal antigens during reproduction, creating a 
'window of vulnerability' during which potential pathogens can enter and infect the female reproductive 
tract [62]. Animal model studies on female pigtail macaques infected with SHIV, showed increased risk of 
infection during or following this high progesterone period [63].  
In addition, concerns remain regarding HIV risk and progestin-based hormonal contraception DMPA, 
which prevent pregnancy by mimicking the luteal phase of the cycle. Rhesus macaque SIV model infected 
with DMPA showed significantly higher acute viremia and delayed virus-specific IFN-γ response [64]. 
Even though the data strongly suggest a role for sex hormones in HIV acquisition, limitations with these 
animal models are also apparent. Differences exist in the biology between human and the animals, therefore 
caution needs to be taken when extrapolating these findings to the context of human infection. 
 
3.4 IMPORTANCE OF SEX CONSIDERATION IN CLINICAL STUDIES 
The preceding discussion illustrates how sex-based differences in immune responses contribute to disease 
susceptibility and severity, which are regulated in part by interactions between sex steroid hormones and 
the immune system. Despite evidence that disease incidence is often different in men and women and 
response to treatment varies, sex-based differences in study design and analyses remain largely excluded in 
clinical trials [30]. Women, in particular are under-enrolled in these studies and this has led to ‘one-drug’ 
treatment regimens for both men and women. Inclusion of sex and gender as variables in clinical trials will 
eliminate discrepancies in both the understanding and the treatment of diseases in the individual sexes.  
In addition, effects of synthetic hormonal contraceptives need to be addressed by conducting larger human 
clinical studies, to determine risk to TB and HIV. This will inform women on risk associated with these 











PROBLEM STATEMENT AND STUDY JUSTIFICATION 
 
Global incidence rates for tuberculosis (TB) indicate a gender-bias to the disease, with almost twice as 
many men actively infected than women (male/female ratio of ~1.7). Sex hormones are known to regulate 
immune function and their role in tuberculosis has been suggested experimentally in animal models as 
described in previous chapters. However the role of sex hormones in human TB infection and whether there 
is any synergistic effect in HIV and TB co-infection is unknown. In addition, data suggests that 
manipulation of sex hormones with progesterone-based contraceptives increases susceptibility to both HIV 
and TB. Therefore our aims for this study were as follows: 
 
 
Aim 1: To develop and optimize a method for quantitation of sex steroid hormones and contraceptive 
analogues in human plasma using a targeted LC-MS/MS approach. 
 
Aim 2: To determine if use of progestin-based contraceptive DMPA is associated with risk of HIV 
acquisition. 
 
Aim 3: To measure adaptive immune responses to TB and HIV infection by means intracellular cytokine 
staining using flow cytometry on peripheral blood mononuclear cells (PBMCs).  
 
Aim 4: To determine phenotypic differences in memory T cell subsets, T regulatory cells and activation 





                         4.0 QUANTIFICATION OF SEX STEROID HORMONES  
 
4.1 INTRODUCTION 
Quantification of sex steroid hormones has in the past, been commonly done using antibody-based 
immunoassays in clinical laboratories. These immunoassays often agree poorly, especially at normal and 
low concentrations due to problems resulting from low assay specificity, sensitivity, inadequate 
standardization, and poor optimization of the methods over the large range of concentrations seen clinically 
[65]. In addition, these assays often suffer from cross-reactivity between structurally similar compounds, 
as is the case for sex steroid hormones (Figure 4.1). Therefore, high-quality steroid hormone measurement 
assays with very good sensitivity, specificity, and reproducibility are therefore essential to the validity of 
epidemiologic studies [66].   
 
The last decade has, therefore, seen an increase in the use of mass spectrometry (MS) for detection, 
identification and quantification of these molecules in complex biological matrices [67], as this technique 
offers superior analytical specificity and accuracy. However, there has been a slow adoption of this method 
as standard means of measuring sex steroid hormones as it is not commonly available in laboratories and 















Figure 4.1 Some major endogenous sex steroid hormones, and contraceptive analogues. Similarities in 
chemical structures may result in cross-reactivity in antibody-based immunoassays such as ELISA. 
 
4.2 MULTIPLE REACTION MONITORING (MRM) 
Liquid chromatography-mass spectrometry (LC-MS) is a powerful analytic technique that combines the 
resolving power of LC with the high sensitivity and specificity of the mass spectrometer (Figure 4.2). The 
technique that is most frequently used in quantitative assays, selected reaction monitoring (SRM, plural 
form: multiple reaction monitoring, MRM) MS was first reported in 1979 during the introduction of the 
triple quadrupole (QqQ) mass spectrometer [67]. Modern liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) with multiple reaction monitoring (MRM) mode provides accurate 
simultaneous quantitation of analytes on large sample sets in a single run, at the same time providing high 
quality information on target molecular profiles in complex biological samples. In this setting, high 
performance liquid chromatography (HPLC) with high resolving power (i.e. ability to resolve analyte peaks 
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to be eluted as discrete peaks) allows for separation of compounds in the chromatographic column. The 
mass spectrometer functions as a unique detector that provides structural information on individual analytes 
as they elute from the LC column [66]. This relies on the discriminating power of mass analyzers to select 
a specific analyte and ion current measurements for quantitation [68]. 
 
 
Figure 4.2 Liquid chromatography- mass spectrometry instrumentation used for MRM analysis. 
 
MRM analysis employs a triple quadrupole MS. The mass spectrometer is equipped with an ionization 
source that impacts a charge, positive or negative depending on selected ionization mode, on each molecule 
as it elutes of out the column. Mostly such assays use electrospray ionization (ESI) followed by two stages 
of mass selection: a first stage (first quadrupole, Q1) selecting only the predefined mass-to-charge (m/z) 
value of the precursor ion of the intact analyte (molecular or parent ion), followed by fragmentation of the 
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parent by collision with argon or nitrogen gas atoms in a high vacuum collision cell (second quadrupole), 
resulting in low energy collisions and fragmentation of the selected precursor ion into many product ions. 
Finally, another mass selection stage (third quadrupole, Q3), selecting specific fragments of the parent 
(fingerprint daughter ions), collectively generates a SRM (or MRM) assay [67, 68]. The two mass filters 
produce a very specific and sensitive response for the selected analyte that can be used to detect and 
integrate a peak in a simple one-dimensional chromatographic separation of the sample [58] (Figure 4.3).  
 
Figure 4.3 MRM scan mode in a triple quadrupole mass spectrometer. (Picture modified from 
mrmatlas.org, accessed on 15 November 2015). 
 
In principle, this mass spectrometry-based approach has the ability to provide absolute structural specificity 
for the analyte, as the resulting daughter transitions give a unique fingerprint for each analyte, and, in 
combination with appropriate stable isotope-labeled internal standards (ISs), it can provide absolute 
quantitation of analyte concentration [68]. 
 
4. 3 QUANTIFICATION METRICS 
 
MRM assays are characterized and their performance assessed based on certain characteristics. As 
mentioned above, accurate and precise quantification is best achieved through addition of a stable 
isotopically labeled internal standard (IS). The ISs are usually spiked into samples far upstream of the 
sample preparation processes and because the ISs are structurally similar to analytes, they introduce only a 
minimal chromatographic shift in the reversed phase chromatography [67]. Signal intensity in the 
chromatogram, that is, area under curve of the IS peak, is compared to peak area of analyte to generate a 




                   
 
                      Peak area ratio (PAR) = peak of analyte / peak area of IS 
 
                      Measured concentration = PAR X IS concentration 
 
As shown in the equation above, measured concentration is determined by multiplying the PAR with 
concentration of IS. A calibration curve, generated from a dilution series of analyte standards prepared with 
IS of fixed concentration and amount is then used to plot these data. If IS concentration is unknown, data 
can be plotted as peak area ratio versus theoretical concentration of calibration standards. Calibration curve 
slope, represents analytical sensitivity of method for that specific analyte [67]. 
 
A limit of detection (LOD) for the assay is determined as the lowest concentration of analyte at which signal 
can be differentiated from noise (usually at ~ signal-to-noise ratio of 3). A limit of quantification (LOQ) is 
described as the lowest concentration of analyte at which quantitative measurement of analyte can made 
with confidence (~S/N ratio of 10) [67]. Different methods for calculating LOD and LOQ have been 
described by Mani et al (2012) [67]. Analysis of samples in replicates allows for determination of precision, 
usually represented by coefficient of variance (%CV) or standard deviation and accuracy. 
 
 
4.4 DEVELOPMENT OF LC-MS/MS METHOD FOR QUANTITATION OF SEX 
HORMONES AND CONTRACEPTIVE ANALOGUES IN PLAMSA. 
 
4.4.1 MATERIALS AND METHODS 
4.4.1.1 Chemicals and reagents 
Progesterone, progesterone-D9, testosterone, epitestosterone, dehyroepiandrosterone and 17-β estradiol 
were purchased from Cerilliant. Norethisterone and ammonium formate were purchased from Sigma 
Aldrich. Commercially available Depo Provera (depot medroxyprogesterone acetate) was used (Pfizer 
Pharmaceuticals). Levonogestrel was extracted from commercially available Trigestrel tablets (Famy Care 
Ltd, India). Charcoal stripped plasma was purchased from Golden West Biologicals Inc. US.  Lypochek 
Immunoassay plus Control Levels 1, 2 and 3 were purchased from Bio-Rad. LC-MS grade methanol, 
hexane, ethyl acetate, acetonitrile, formic acid, acetone and water were purchased from Sigma Aldrich. 
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1.5ml auto sampler vials, caps with PTFE lined silicone septa, glass micro-inserts were purchased from 
Separations.  
 
4.4.1.2 LC-MS/MS system 
Analyte concentrations in plasma samples were measured by HPLC tandem mass spectrometry, using an 
Agilent Technologies 1200 Series HPLC with a Phenomenex C-18 (50 X 2.10mm) analytical column 
maintained at 4oC. The sample injection volume was 20 µl and mobile phases were water (A) and 
acetonitrile (B) with 0.1% formic acid. The column was developed by step-wise linear gradient elution as 
follows: 0.00min, 20%B; 0.10min, 20%B; 5.10min, 100%B; 15.00min, 100%B; 15.10min, 20%B and 
23.00min 20%B. A constant flow rate of 200µl/min was maintained. Analytes were detected on an 
ABSciEx Q-TRAP 5500 mass spectrometer using electrospray ionization in a positive ion mode and 
multiple reaction monitoring to measure the precursor-to-product ion transition. All analyses were 
performed using Analyst Software (version 1.6) and quantitation values generated using the respective 
standard curves for each analyte. The total LC-MS/MS rum time was 23 minutes per sample analyzed. 
Optimized settings are summarized in Tables 4.1 and 4.2.  
 
Table 4.1 Electrospray ionization (ESI) settings 
Curtain gas (CUR)  
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Ion spray voltage (V)  
 
4500 
Source temperature (°C)  
 
350 
Gas 1 (psi)  
 
40 
Gas 2 (psi) 40 
 
 
4.4.1.3 Sample preparation 
Frozen plasma samples, quality control samples and double charcoal stripped plasma (-80oC) were thawed 
on ice and 85µl removed for analysis. Calibration standards (0.01 to 10ng/ml) were prepared by adding 
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progesterone, testosterone, norethisterone, epitestosterone and DMPA in methanol to double charcoal 
stripped plasma. As an internal standard 10µl of progesterone-D9 (103nM) was added to all samples, 
vortexed and equilibrated for an hour. Calibrators, quality control samples and plasma samples were then 
extracted by addition of 825ul ethyl acetate-hexane (80:20), vortexing for 2 minutes, and centrifuging at 
300 xg for 5 minutes. The upper organic layer (600ul) was transferred to a new tube and washed with 50ul 
ammonium formate buffer (0.1M, pH 9.0). 500ul of organic phase was then removed and transferred to a 
new vial, evaporated to dryness under nitrogen gas and then re-constituted in 200ul H2O: formic acid: 
MeOH (49: 0.1: 50), vortexed and transferred into micro-inserts and in auto sampler glass vials. 
 
4.4.1.4 Preparation of internal standard (IS) solution 
For quantitation accuracy and precision a deuterated internal standard (IS) with nearly similar chemical 
properties was used, namely progesterone-D9. The progesterone-D9 internal standard was purchased as a 
100µg/ml solution in acetonitrile (Cerilliant) and stored at -200C. Working stock of the IS (103nM) was 
prepared by dilution in methanol, instead of acetonitrile as this solvent caused precipitation of plasma 
sample when IS was added during extraction. IS stock and working solution were stored at -20°C. 
 
4.4.1.5 Preparation of standard stock solutions  
Stock solutions of all analytes were prepared at a concentration of 1 mg/ml in acetonitrile except for DHEA, 
which was prepared in methanol because of its solubility. For each analyte, a substock was prepared in 
acetonitrile at 10µg/ml. These substock solutions were used to prepare working solutions to spike double 
charcoal stripped plasma as required. All stock solutions were stored at -20°C.
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Table 4.2 MS/MS settings 
 Progesterone 
D9 
Progesterone Testosterone DMPA Norethisterone Levonogestrel Epitestosterone DHEA 
Q1 mass 
[M+H]+ 





97.000 97.000 327.100 91.000 107.000 97.000 253.100 
De-clustering 
potential (V) 
71 86 71 126 66 116 89 136 
Collision 
energy (V) 




16 18 8 14 14 18 14 10 
Scan type MRM MRM MRM MRM MRM MRM MRM MRM 
Polarity Positive Positive Positive Positive Positive Positive Positive Positive 
Pause time 
(ms) 





4.4.1.6 Preparation of calibration standards and quality control standards 
A set of calibration standards were prepared volumetrically in double charcoal stripped plasma. A working 
stock solution of mixed analytes was prepared at a concentration of 105ng/ml mixed standard solution 
(MSS1) by adding 52.5µl of each 10µg/ml analyte substock in a 5ml volumetric flask and filled up to the 
mark with 90% methanol. MMSI was then serially diluted with 90% methanol to attain the desired standard 
working solutions (STD1-8). 10ul of each STD was then spiked into 85µl double charcoal stripped plasma 
volume to give desired concentration range of 0.01 – 10ng/ml as presented in Table 4.3. From the calibration 
curve, the limit of detection (LOD) and lower limit of quantification (LOQ) were determined. 
 
Quality control samples (QC1, low, QC2, medium and QC3, high) were purchased with added 
progesterone, 17β-estradiol and testosterone at fixed concentrations, however all other analytes  were added 
into QC samples by spiking 10µl of prepared analyte solutions to give final concentrations of 0.7, 2.5 and 




 Table 4.3 Preparation of calibration standards for all analytes. 
Standard Volume MSS1 added 
(µl) 
Volume of 90% 
MeOH diluent (µl) 
Total 
volume (µl)  
Volume added to 
double charcoal 
stripped plasma (µl)  
Final standard 
concentration (ng/ml) 
STD8 1000 0 1000 10 10 
STD7 999 1 1000 10 5 
STD6 995 5 1000 10 1 
STD5 990 10 1000 10 0.5 
STD4 950 50 1000 10 0.1 
STD3 900 100 1000 10 0.05 
STD2 500 500 1000 10 0.01 
STD1 
(blank) 







4.4.1.7 Calibration standard curve 
Double charcoal stripped plasma and QCs stored at -80°C, were thawed, spiked with appropriate STD as 
indicated in Table 4.3, extracted using the protocol described in section 4.4.1.3 and analysed for each 
validation run. Using Analyst® software standard curve fitting was determined by applying the simplest 
model that adequately describes the concentration vs response relationship using appropriate weighting. 
The calibration curve is comprised of eight different STDs including the blank, with concentrations ranging 
from 0.01 ng/ml to 10 ng/ml. For quantitation the eight-point calibration standard curves were calculated 
based on peak area ratios of analyte to IS and fitted using 1/x (1/concentration) weighted linear regression, 
which was found to be the simplest regression model for quantification. Representative calibration curves 
for DMPA, progesterone and testosterone are presented in Figure 4.4a-c. 
 
 









Figure 4.4b. Representative calibration curve for progesterone. 
 





4.5 RESULTS AND DISCUSSION 
4.5.1 Mass spectrometry 
Since emergence of MRM analysis, a number of studies have been done on sex steroid hormone quantitation 
using MS. The first step was initial tuning of the mass spectrometer to determine ionization of analytes. 
Relevant literature was searched to determine expected parent ions and daughter transitions using ESI, and 
also previously established ionization mode for each analyte [69, 70]. Optimization of MS transitions was 
done by diluting analyte substock solutions in methanol, to lower concentrations, between 40 and 100ng/ml. 
Direct syringe infusion into the mass spectrometer, of a constant stream of an analyte at a given time was 
done and expected molecular ion was scanned in a pre-selected range of [M+H]+ ions. Transitions (m/z), 
resulting from this specific parent ion were scanned and the most abundant 5 transitions were selected from 
the mass spectrum to maximize sensitivity. Furthermore, for each species, two ion pairs were chosen, with 
the most sensitive transition being used for quantitation (quantifier) and the other transition being used for 
confirmation (qualifier). Figure 4.5a and b, illustrate mass spectra of two of the analytes optimized, 
progesterone and the internal standard, progesterone- D9.  
 
 
Figure 4.5 Mass spectrum for progesterone showing molecular  ion peak [M+H]+ m/z 315.2 ---> 97.0 and 




Figure 4.6 Mass spectrum for internal standard progesterone-D9, showing molecular  ion peak [M+H]+ m/z 
324.2 ---> 100.0 and 324.2 --->113.0 m/z transitions. 
 
Mass spectra obtained during optimization in positive ESI mode, showed a protonated molecular ion 
[M+H]+ for all steroids except for DHEA for which, a protonated molecular ion with loss of water, [M-
H2O+H]+ was observed as previously reported in other studies. [71]. All optimized analytes and their 











Table 4.4 Molecular ion, quantifier and qualifier transition, m/z for all optimized analytes in ESI positive 
mode 
   
Analyte 







Progesterone- D9 324.2 100.0 113.0 
Progesterone 315.2 97.0 109.0 
Testosterone 289.2 97.0 109.0 
Epitestosterone 289.2 97.0 109.0 
DHEA 271.2 213.1 253.1 
Levonogestrel (active compound 
in some oral contraceptives) 
313.2 107.0 109.0 
DMPA (Depo Provera) 387.2 122.9 327.1 
Norethisterone (Nuristerate or 
Net-En) 
299.2 65.1 91.0 
 
 
4.5.2 Chromatography  
Chromatographic separation was achieved using a step-wise linear gradient elution, with changes in mobile 
phase composition ratios with time.  Mobile phase A, water was used in conjunction with mobile phase B, 
acetonitrile in the presence of 0.1% formic acid. Formic acid is added to mobile phase mixture, to aid in 
improving ionization of analytes by donating protons [H]+. The column temperature was set at 400C and a 
flow rate of 200µl/min was maintained. Optimal time of 23 minutes for each gradient run allowed for 
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elution of all analytes with good peak resolution and peak shape, as well time for clean-up of column for 
the next run. 
 
 
Figure 4.7  Examples of chromatograms showing analayte peaks and different retention times for A)  
progesterone, B) DMPA, C) testosterone and  D) internal standard, progesterone-D9 
 
Quantitation of each analyte, as previously described, was done using analyte peak area ratio to peak area 
ratio of IS, progesterone-D9 of known concentration. Peak area ratios were then computed against the 
calibration curve to determine the unknown. 
 
4.5.3 LC-MS/MS METHOD VALIDATION 
A good method validation consists of a set of calibration standards and quality control assessment run on 
different occasions to ascertain that the method is accurate, precise and reproducible. The QC samples are 
monitored over validation batches performed on three different occasions to determine intra-batch and inter-
batch accuracy and precision. 
 
Intra-batch and inter-batch accuracy and precision assessment 
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QC samples were extracted and prepared in parallel with the biological samples and injected at the 
beginning, in the middle and at the end of every analytical run to monitor the consistency of instrument 
performance throughout the analytical run – intra batch accuracy and precision.  The QC samples were also 
monitored over successive batches performed on different days to ascertain inter-batch accuracy and 
precision. Pooled plasma sample were prepared from healthy controls (HCPP) and actual study samples 
(SPP) and were processed with each batch to determine batch processing variation.  
From the results presented in Tables 4.5 and 4.6, it may be concluded that the method performed effectively 
between and within batch runs as all QC and pooled plasma samples have a calculated % CV of less than 
15%. 
 







CV (%) n 
progesterone QC1 0.658 0.070 10.7 17 
 QC2 5.559 0.46 8.3 17 
 QC3 14.806 1.23 8.4 17 
 HCPP 3.494 0.27 7.8 17 
 SPP 1.498 0.15 10.4 17 
testosterone QC1 0.875 0.13 14.7 17 
 QC2 3.879 0.47 12.2 17 
 QC3 6.225 0.83 13.4 17 
 HCPP 2.325 0.13 5.7 17 
















CV (%) n 
progesterone QC1 0.678 0.080 11.8 6 
 QC2 5.763 0.33 5.8 6 
 QC3 16 0.74 4.6 6 
 HCPP 3.667 0.24 6.5 6 
 SPP 1.565 0.22 14.3 6 
testosterone QC1 0.884 0.068 7.7 6 
 QC2 4.207 0.22 5.2 6 
 QC3 6.650 0.61 9.2 6 
 HCPP 2.475 0.081 3.3 6 
 SPP 1.078 0.11 10.3 6 
 
Stability Assessment 
For method validation it is also necessary to ensure that the analytes are stable (do not degrade) throughout 
the sample preparation, extraction and analytical procedure including associated conditions such as 
temperature variations. Stability of steroid hormones in plasma or serum and stock solutions has been 
previously demonstrated. Previous studies have shown no significant analyte losses up to 3 free-thaw cycles 
and also post-extraction stability for up to 3 days at 100C in the autosampler [71, 72]. All sample freeze-
thaw cycles were kept to a maximum of 2, to minimize degradation of analytes and batches were run over 
a maximum period of 3 days. Manufacturer’s storage instructions for standard stocks were followed 
(storage at -200C). Plasma sample handling was kept to a minimum and on-bench processing was done on 
ice.  
Specificity and sensitivity  
A method should be selective for a specific analyte and not be affected by interfering or co-eluting 
components in the biological matrix. Any interference would be most apparent at low analyte concentration 
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levels. The selection of a specific precursor ion followed by the formation and detection of a specific 
product ion renders quantitative mass spectrometry highly specific.  
A representative chromatogram of a plasma sample is presented in Figure 4.8, indicating both progesterone 
and progesterone-D9 peaks with no interfering peaks. The method is specific for the quantitation of each 
analyte from human plasma samples as indicated by the different m/z transitions resulting from the 
molecular ions and different elution times of both analytes, even though progesterone and the deuterated 
form are identical in structure, with only a difference of heavier isotope of hydrogen in the deuterated form. 
 
 
Figure 4.8 An example of a chromatogram of progesterone and internal standard, progesterone-D9. 
 
A linear calibration curve can be used to determine sensitivity of method for a specific analyte. This allows 
for determination of LOD and LOQ parameters using the regression equation of the calibration curve. The 
standard error Sy|x of the measured concentration (y-estimate in the regression equation) and slope of the 
equation are to determine LOD and LOQ as follows: 
  
                         LOD = 3 Sy|x/slope 
                         LOQ = 10 Sy|x/slope 
 
Table 4.7 Determination of LOD and LOQ from linear calibration curve. 






DMPA 0.9993 0.213 0.00055 0.0010 0.015 0.046 
Progesterone 0.9977 0.254 0.00608 0.0022 0.029 0.087 
Testosterone 0.9987 0.351 0.00695 0.0042 0.039 0.11 





Also known as ion suppression, is a phenomena that occurs because ionization of analyte of interest is 
susceptible to disturbance from other components of the biological samples that co-elute with the analyte. 
This can either cause suppression or enhancement of analyte peak. This effect was not tested during method 
development, however to reduce this effect two steps were taken,  
i) During sample preparation, a wash step with ammonium formate (pH 9.0, 0.1M) was 
performed. This removes molecules that may cause interference in steroid ionization such as 
phospholipids 
ii) Compensation with a stable isotopically labelled internal standard (IS) ensures a consistent 
effect as both IS and analytes undergo same amount of matrix effect. 
Sample recovery 
A sample preparation method is required that can balance cleaning up of samples to remove as many 
interferences as possible while achieving maximal recovery of analytes. To achieve this, the isotopically 
labeled internal standard, progesterone-D9 was spiked pre- and post- extraction of quality control samples. 
Ideally spiking a blank matrix such as charcoal stripped plasma is preferred, however due to limited 
resources at the time, QC samples were used. Percentage recovery is calculated using the equation: 
  
Peak area of analyte before extraction / peak area of analyte after extraction X 100 = % recovery 
In Table 4.8, recovery of progesterone-D9 was 56-63%, which is a moderate recovery indicating a certain 
level of analyte losses.  This may be due to the additional wash step for removal of interfering molecules 
in the plasma samples. Also, for extraction process, plastic microtubes were used, and this may not be ideal 
for steroids hormones since they are lipid-like in nature and could form non-polar interactions with 
microtube walls, causing losses of analyte. This could, in the future be improved by use of glass microtubes. 








Table 4.8 Determination percentage recovery of progesterone-D9. 
 Mean peak area 
spiked 
before extraction 




QC1 1.89 x106 3.29 x106 56 
QC2 2.17 x106 3.43 x106 63 
QC3 2.26 x106 3.92 x106 58 
 
 
4.5.4 Challenges with 17-β estradiol optimization 
Previous studies have reported measurement of 17-β estradiol (E2) in serum or plasma samples as a major 
challenge due to low concentrations normally found in these samples (pg/ml range). This represents a 
challenge in particular, in serum or plasma from children, men and postmenopausal women who have very 
low circulating levels of E2 and therefore would require highest level of sensitivity for analysis. In 
premenopausal women, E2 levels also fluctuate during the menstrual cycle, however, even if E2 
concentrations are higher in this group, they are still below 55pg/ml except at ovulation and in pregnancy, 
which requires considerable assay sensitivity [69]. 
Previous studies have described MRM analysis of E2 using ESI ionization mode. MS optimization of ion 
pair of molecular ion to daughter ion was done in both negative and positive mode of ESI. The molecular 
ion was scanned successfully in both modes, [M-H]- -->271 and [M+H]+ --> 273 respectively, however as 
seen in both Figure 4.9a and b, ionization efficiency for E2, which lacks highly ionizable functional groups 
is relatively low using ESI mode as indicated by absence of prominent daughter transitions. Successful E2 
ionization in ESI using both negative and positive mode, has been described before, however a number of 
studies describe poor ionizability therefore sensitivity at pictogram levels is difficult to achieve. Therefore 
to improve ionization, studies have used other more harsh ionization modes such as atmospheric pressure 
chemical ionization (APCI) or atmospheric pressure photoionization (APPI) [73]. However, due to 











Figure 4.9a and b, mass spectra of E2 in negative and positive ESI mode respectively. 
Molecular ion peak[M-
H]- 






Recent years have seen new methods that utilize the introduction of a highly ionizable functional group into 
steroid molecules to significantly enhance the ionization efficiencies of various steroid hormones, a process 
called derivatization. The derivatization of estrogens with a dansyl functional group has been reported [74, 
75], using ESI, APCI or APPI positive ionization mode. Use of 4-(dimethylamino) benzoyl chloride 
(DMABC), as a more versatile and more sensitive derivatizing agent for ESI source has also been described. 
Hence, we optimized a reaction between DMABC dissolved in dry acetone and excess E2 standard solution 
(100ng/ml) by heating at 600C for 6min (heating for longer, 25 minutes, did not improve peak intensity). In 




Figure 4.10 Mass spectrum of DMABC-derivatized 17-β estradiol. 
 
Using the same method of E2 derivatization, E2 standard solution of 100ng/ml, and female plasma samples 
were prepared. However, we did not observe the expected peak in actual female plasma samples, only in 
high concentration derivatized E2 standard. From this we conclude that even though we successfully 
optimized derivatized E2 transitions, and column separation, as seen in high concentration E2, our method 
however is not sensitive enough to detect E2 at physiological level. We propose that the sample extraction 





method may be limiting. Other studies have overcome this by using solid-phase extraction (SPE) to 
concentrate the sample before injection into the LC system. Therefore, our future work will investigate use 




We have developed a LC-MS/MS method that allows specific and simultaneous detection of multiple sex 
hormones and contraceptive analogues in human plasma, and quantification with good sensitivity, with the 
exception of 17-β estradiol. Investigation of SPE in sample processing and use other ionization techniques 
such as APCI and APPI, for measurement of 17-β estradiol, need to be investigated to improve method 
sensitivity for this analyte. Observed limits of detection and quantification were in the lower pg/ml range 
and comparable with what has been shown in other studies. This method is simple, requires a small sample 
volume and sample preparation is minimal. It also provides sufficient sensitivity, which allows for 
















5.0 INJECTABLE HORMONAL CONTRACEPTIVES AND ASSOCIATION WITH HIV 
RISK 
 
5.1 LITERATURE REVIEW 
 
A number of studies have associated the use of hormonal injectable contraceptives, and particularly 
progestin-based DMPA, with increased risk in HIV acquisition [76, 77, 78]. A systematic review by Polis 
et al, (2014) points out that, some studies however report no statistical significant increased risk with both 
DMPA and Net-En [79]. Therefore a lot of controversy still remains about the validity of these observations 
given the high potential for confounding factors such as potential risky sexual behavior among hormonal 
contraceptive users. 
Studies in non-human primate models using simian immunodeficiency virus (SIV) and simian-human 
immunodeficiency virus (SHIV) represent a good model to study this effect as these are free from 
confounding factors. For example, treatment of macaque with DMPA results in increased susceptibility to 
both SIV and HIV infection compared to untreated controls [64, 80]. This increased susceptibility in 
SIV/SHIV infection in DMPA treated macaques was attributed to changes in the vaginal epithelium [80]. 
Limitations, however, exist in these studies, which include small numbers of animals and differences in 
species, dosage, and study design. Human studies specifically designed to determine impact of DMPA or 
other hormonal contraceptives on HIV risk need to adjust for the variability of human behavior such as 
sexual exposure, condom use amongst other factors, which presents a significant challenge [81]. 
 
AIMS 
a) To validate LC-MS/MS method for quantitation of sex hormones and hormonal contraceptives, 
in real biological samples. 
 
b) To determine if hormonal contraceptive use is associated with higher risk of HIV acquisition. 
 
To study this we collaborated on two separate cohorts, in which DMPA levels in plasma samples were 
measured. In the CAPRISA cohort, cervicovaginal samples were analysed using shotgun proteomics and 




5.2 MATERIALS AND METHODS 
5.2.1 Ethics statement 
Ethical approval for the FRESH cohort study was obtained from the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal (Durban, South Africa) and the Massachusetts General 
Hospital Institutional Review Board (Protocol 2012P001812/MGH; Boston, MA). 
Ethical clearance for the CAPRISA 004 study was obtained from the BREC of the University of KwaZulu-
Natal, (Durban, South Africa), ref. E111/06 and University of Manitoba Institutional Review Board 
(Canada).  
 
5.2.2 Study design 
For the CAPRISA pilot study, study participants were a subset of 38 cases and controls selected from the 
CAPRISA CAP004 study. This study enrolled high risk HIV negative women between 18-40 years, in a 
double-blinded, randomized, placebo-controlled trial to assess effectiveness of tenofovir gel against HIV 
infection. If any of the women became HIV-infected, they were then enrolled in the CAP002 arm.  Women 
were enrolled at CAPRISA Vulindlela clinic and eThekwini Research clinic for. All participants provided 
written informed consent. 
 
The FRESH cohort study was part of an observational, closed cohort, prospective study conducted in 
Umlazi, South Africa. Participants were HIV-negative women ages 18-23, recruited for the Females Rising 
through Education, Support, and Health (FRESH) study. Twice per week, participants attended classes 
focused on personal empowerment, job skills training, and HIV prevention. HIV-1 testing is done twice-
weekly and demographic and behavioral data is collected in addition to blood and cervical samples. 
Informed consent was obtained from all participants.  
 
5.2.3 Measurement of sex hormones and contraceptives using LC-MS/MS. 
All instrumentation set-up, reagents and plasma sample preparation protocols for quantitation of sex steroid 
hormones has been described in Chapter 4. 
 
5.2.4 Proteomic analysis of vaginal lavage samples from the CAPRISA study 
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Proteomic analysis of matched cervicovaginal lavage samples was done at the University of Manitoba by 
collaborators. (See contributions). 
 
 5.2.5 Statistical analyses 
All sex hormones measurement analysis was performed using GraphPad Prism software, version 6.0. In the 
CAPRISA 004 study, statistical differences in DMPA, progesterone and testosterone levels were 
determined using one-way ANOVA tests, and Bonferroni multiple comparisons test. Correlation between 
progesterone and DMPA was determined using a Pearson’s r correlation (p-value, one tailed). Shotgun 
proteomic analysis of CVL samples, was perfomed by our collaborators, and is not discussed here. 
 
5.3 RESULTS  
To validate our LC-MS/MS method in real biological specimens, we collaborated on two separate blinded 
studies, looking at risk of hormonal contraceptives in HIV. In the first instance, we analyzed female plasma 
samples from the CAPRISA CAP004 study (n = 38). Samples were prepared and analysed using the 
extraction protocol and optimized instrument settings, described in Chapter 4. Once un-blinded, samples 
were stratified according to contraceptive use. We had 21 samples for Depo-Provera contraceptive users, 8 
samples of oral contraceptive (OC) users, 5 samples of Nuristerate (Net-EN) users, and 1 sample from a 
patient who underwent tubal ligation (not included in analysis). DMPA, is the active compound in the long-
term injectable contraceptive Depo Provera. As shown in Figure 5.1, Depo Provera users had significantly 
higher levels of DMPA in their plasma compared to OC and Net-EN users (p = 0.0167 and 0.0262 
respectively). For OC and Net-EN users, DMPA levels were near or below both the LOD and LOQ, 
indicating absence of DMPA except for 1 patient sample in the Net-EN group who had significantly high 
DMPA levels.  
 
Next we examined levels of natural progesterone in these subjects, as Depo Provera is known to directly 
inhibit the production of endogenous progesterone [82, 83]. As expected subjects with detectable DMPA 
levels in general have lower levels of endogenous progesterone than those not taking Depo Provera (Figure 
5.1). This difference is not significant, although that is perhaps not unexpected as subjects not using Depo 
Provera are still subject to natural cyclic changes in progesterone. In addition, one might expect quantity of 
DMPA present to impact on the extent to which natural progesterone is suppressed. To test this we 
correlated progesterone and DMPA in the subjects taking Depo Provera and observed a significant inverse 
correlation (r2 = 0.1537, r = -0.3920, p= 0.0437), despite the small sample size (Figure 5.2). This indicates 
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that as DMPA levels wane, their modulatory effect is also likely to decline, which in turn may influence 






























































































Figure 5.1. Plasma DMPA and progesterone levels measured using LC-MS/MS in individuals on different 
contraceptive methods. 
 












































Figure 5.2 Plot showing DMPA-progesterone correlation. 
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Sex hormones and hormonal contraceptives are known to modulate changes in the female reproductive tract 
environment. There are several biologically plausible mechanisms by which hormonal contraceptives could 
increase HIV risk including disrupting epithelial barriers, causing changes in inflammatory responses that 
could in turn enhance HIV replication locally, or by altering the vaginal microbiota which itself effects 
local immunity and genital inflammation [84].  
 
To investigate if hormonal contraceptive DMPA directly affects the female reproductive tract we next 
examined the proteome of the cervix of Depo- Provera users, measured by our collaborators in 
cervicovaginal lavage (CVL) samples obtained from the same subjects and at the same time point. CVL 
proteome was analyzed using shotgun proteomics, and the proteins identified were correlated with DMPA 
levels using the linear univariate Pearson correlations. Table 5.1 shows the proteins significantly associated 























All samples (DMPA, Net-En and OC users), were then grouped into high, medium and low DMPA levels 
using arbitrary cut-offs based on distribution of data. A LASSO (least absolute shrinkage and selection 
operator) and PLSDA (partial least-squares discriminant analysis) were used to identify a set of proteins 
that best differentiated the groups. In Figure 5.3 LV1 (latent variable 1) is a regression score for the linear 
combination of proteins that best differentiate the groups, and LV2, is the second best. Each dot is an 
individual, coloured by 3 groups: red-high, green-medium and blue-low DMPA levels. PLSDA tries to pull 
these three groups apart to see maximum differences. The loadings plot shows the proteins that are 
associated with the groups and a full description of the proteins is given in Table 5.1. Although preliminary, 
these data strongly suggest that Depo Provera use significantly impacts on the female genital tract proteome 




Figure 5.3 Protein signature associated with high, medium and low DMPA levels. PLSDA w/ LASSO 
(Least Absolute Shrinkage and Selection Operator) is used to identify a protein signature that best classified 
high (red), medium (green) and low (blue) groups, with calibration error = 0.13321 and cross validation = 





Table 5.2 List of CVL proteins found to be differentially expressed in high, medium and low DMPA levels. 
Protein Full Name 1General function 
CADH1 Cadherin-1 Epithelial adhesion protein 
ANXA8 Annexin A8 Anti-coagulation 
DSG1 Desmoglein-1 Intercellular junctions, cell-cell adhesion 
K1C14 Keratin, type I cytoskeletal 14  Structural, keratin filament binding 
LV106 Ig lambda chain V-I region WAH Antigen binding 
SPR2D Small proline-rich protein 2D Keratinization 
GSTM4 Glutathione S-transferase Mu 4 Enzyme binding, glutathione transferase 
activity 
C4BPA C4b-binding protein alpha chain Compliment activation, classical pathway 
CLCB Clathrin light chain B Intracellular protein transport, endocytosis 
K2C4 Keratin, type II cytoskeletal 4 Structural, cytoskeleton organization 
SPB4 Serpin B4 Protease inhibitor 
MOES Moesin Cell-adhesion binding molecule  
SAP Proactivator polypeptide Enzyme activator activity 
KLK3 Prostate-specific antigen Hydrolase activity, liquefaction of seminal 
coagulum 
NDKB Nucleoside diphosphate kinase B Nucleotide metabolism 
1 General functions are based on each protein’s gene ontology obtained from the UniProt website. 
 
This preliminary data forms part of an ongoing study, investigating changes in CVL proteomic signatures 
in Depo Provera users followed over time. Longitudinal analysis of DMPA concentrations in biological 
samples will allow us to profile the DMPA decay curve over time and determine if the high or low levels 
are associated with infection time points. For example in Figure 5.4, we show DMPA decay profiles of 5 
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of the 14 patients that have already been analyzed. This is an ongoing study, with approximately 700 more 
samples yet to be analyzed. Although also somewhat preliminary in nature it is apparent from these data 
that decay rates of DMPA are variable between individuals. Presumably, levels remain above that required 
for activity as a contraceptive agent. However, the level at which DMPA influence the immune response 
may be quite different. This, therefore again, highlights the potential importance of being able to directly 
quantify DMPA levels rather than rely on reporting times for the last injection. 
 
 
Figure 5.4 Longitudinal profiling of DMPA decay curve in 5 patients using Depo Provera (DMPA). 
  
A second cohort was also used for validation of our LC-MS/MS method, the FRESH cohort. To investigate 
effects of DMPA levels on risk of HIV acquisition, a blinded analysis of female plasma samples (n = 62) 
was done to determine DMPA levels. When un-blinded, patients were stratified according to their 
contraceptive use (Table 5.2). 38 of the total of 44 self-reported Depo-Provera users had significant levels 
of DMPA while 4 were negative (below limit of quantification) by mass spectrometry. Of the non- Depo-










Individuals in this study, were enrolled as HIV negative. Despite intensive counseling and education, 24 
women became HIV infected by the time of analysis. An analysis done by our collaborators showed that 
injectable progestin-based contraceptive users (DMPA and Net-En) combined had a higher risk of HIV 
acquisition compared to non-family planning users (p=0.0142) (Figure 5.4). There was no association 
between increase in DMPA levels and increase in risk of HIV acquisition. 
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Figure 5.5 HIV incidence comparison between no family planning group and injectable progestin-based 
contraception (IPC) group. P-value in Kaplan-Meier curve determined by a log-rank test (Manuscript 




Measurement of sex hormones and hormonal contraceptives using mass spectrometry allows for 
identification and quantitation of these biological molecules with high specificity and sensitivity. With 
regards to contraception use, this method has the potential in clinical studies, to eliminate the need to rely 
on self-reported information, on what contraceptive they could be using. For example, in Figure 5.1, a 
patient classified in the Net-En users group had significantly high levels of DMPA in their plasma. In Table 
4.4, we show that these two molecules have structurally different molecular ion peaks and m/z transitions 
(norethisterone: 299.161--->91.000; 299.161--->65.100 and DMPA: 387.003--->327.100; 387.003---
>122.900). Such highly levels of DMPA could mean that this patient misreported information on their 
health questionnaire or alternatively, since injections are administered at hospitals and clinics, patients may 
be misinformed on which contraceptive they are using. Another explanation could be that the patient was 
using Net-EN upon enrolment but had subsequently changed to Depo-Provera injection when the sample 
was obtained. Even in a tightly followed cohort as the FRESH cohort, there were some inconsistencies in 
reporting, which could be explained as indicated in Table 5.3. Therefore this suggests a huge potential for 
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mass spectrometry methods, not only for quantitation of molecules but for identification of exogenous 
molecules in biological samples to eliminate errors associated with self-reported information. 
 
In Figure 5.1, a decrease in progesterone levels in both Depo-Provera and Net-EN users is observed 
compared with OC users, though not significant, suggesting that Net-En may also modulate progesterone 
levels in a similar mechanism to DMPA. However since Net-En is only a two-month acting injectable 
compared to the three-month for DMPA, it is not as strong a suppressor of progesterone as DMPA. DMPA 
inhibits ovulation by suppressing levels of the luteinizing hormone (LH) and follicular-stimulating hormone 
(FSH), subsequently serum progesterone levels remain low (< 0.4 ng/mL) for several months following an 
injection of DMPA [82, 83]. As such, we observed a negative correlation between progesterone and DMPA 
levels, as expected. There were no significant differences in testosterone levels between the groups, 
suggesting that testosterone levels may remain unaffected by contraception use. 
 
The female genital tract possesses several mechanisms of protection including epithelial barrier of the 
vagina and cervix, immune cells, and various molecules secreted by epithelial cells, immune cells, and 
microbiota [81]. For initiation of infection in the FRT, HIV must infect the highly susceptible cervical and 
vaginal immune cells in the submucosa, which are protected by either the squamous or single layer 
columnar epithelium of the cervical or vaginal compartments, respectively.  [85]. FRT secretory proteins 
have been shown to have the ability to provide protection against HIV and other sexually transmitted 
infections in vitro, but changes in their expression may facilitate HIV infection by activating target cells or 
increasing viral replication. Changes in the expression of these soluble mediators have been observed 
throughout the menstrual cycle and during pregnancy, providing support for the hypothesis that 
reproductive hormones may increase HIV risk through modulation of soluble mucosal defense. [81]. 
Comprehensive qualitative proteomic studies on cervicovaginal samples show that this matrix contains 
proteins/peptides with intrinsic anti-HIV activity such as defensins, lactoferrin, lysozyme, cathelicidin and 
SLPI [86, 87]. A decrease expression of an anti-inflammatory serine protease inhibitor, SPLI, known to 
have anti-HIV activity was observed after treatment with DMPA [88]. However, the effect of exogenous 
hormones, particularly DMPA on changes in cervical and vaginal proteome has been less studied.  
 
Our aim was therefore to study changes in the proteome of CVL samples in women with varying levels of 
DMPA. A number of proteins were positively correlated with DMPA levels, as shown in Table 5.1.  Some 
of these proteins form part of the cytoskeleton and are necessary for structural integrity of the epithelia, 
such as, K1C15, POF1B, FILA and KRT85 amongst others. PCSA and ZN185 are known for regulation of 
cell proliferation and/or differentiation. SEMG1, a semen protein was negatively correlated with DMPA 
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levels. Some proteins have been previously shown to play a role in HIV infection, or at least in the 
susceptibility of the female reproductive tract to viral infections, such as ANXA2, MUC4, and MUC5A. 
Annexin 2 (ANXA2), was shown to bind Gag protein and associated with increase in infectivity of virion 
particles in monocyte-derived macrophages [89]. However, Rai et al (2010), showed that Annexin 2 is 
rather involved in a cell type-dependent role in regulating production of infectious HIV-1 by macrophages 
than HIV-1 virion particle production [90]. MUC4 and MUC5A are mucus proteins secreted by epithelial 
cells for mucosal protection. These mucins are found in the cervicovaginal mucus, which has been shown 
to have activity that hinders HIV-1 movement. [91]. Therefore downregulation of gel-forming MUC5A by 
DMPA may aid in increasing risk of HIV acquisition. 
In the PLSDA analysis, a cluster of 5 proteins in the PC1 vs PC2 plot, were found to be associated with 
high levels of DMPA: MOES, NDKB, KLK3, SAP and SPB4. A study by Barrero-Villar suggests that 
Moesin (MOES), a cell adhesion molecule may facilitate HIV-1-induced CD4-CXCR4 interaction and 
therefore efficient HIV-1 viral fusion and infection [92]. Therefore upregulation of MOES at high DMPA 
levels may play a role in increased risk of HIV infection. Serpin B4 (SPB4) is known to have anti-HIV 
activity, and was shown in the study by Burgener et al, (2008) to be overexpressed in HIV-resistant women 
[93]. On contrary, we observe an association of SPB4 with high DMPA levels and DMPA has been 
suggested to increase risk of HIV. 
 
In the FRESH cohort study, a higher risk of HIV acquisition is observed among the IPC users compared to 
individuals not using any form of contraception (Figure 5.5). Although both DMPA and Net-En were 
associated with greater risk of HIV acquisition, Net-En conferred a particularly high risk compared to 
DMPA. The findings of association of IPCs with increased HIV risk, are in agreement with some of the 
published studies [79], however, contrary to other studies who have reported no risk for Net-En or even for 
DMPA [94, 95, 96]. Limitations of prior studies are confounding factors, mainly due to differences in 
behavioral risk between non- hormonal contraceptive users, and long-term injectable DMPA and/or Net-
En users. In this cohort, one of the strengths is that potential confounders such as condom use, sexual 
behavior, and differences in age were assessed and controlled for. A biological explanation for this observed 
increased risk amongst IPC users, was the observation of an increase in CCR5+CD4+ T cells and also an 
increase in expression level of CCR5 in CD4+ T cells in the cervix compared to no family planning group 
(manuscript in Appendix section). CCR5 co-receptor is used for entry by HIV into CD4+ T cells, therefore 
increased expression of these HIV target cells in the cervix provides a possible explanation for increased 





We have used mass spectrometry methods for detection and quantitation of exogenous and endogenous sex 
hormone levels, which is a very reliable tool as it eliminates uncertainties associated with self-reported 
information by patients. We observe an association of injectable contraceptives with protein signatures that 
have been previously shown to play a role in HIV infection, and also an increase in HIV target cells in the 
cervical compartment of IPC users. These findings suggests a role for IPC in HIV acquisition. 
Therefore women using progestin-only injectable contraceptives such as DMPA or NET-EN should be 
informed on the current observation of possible increased risk of HIV acquisition associated with these 
hormonal contraceptive methods. This will help women make more informed choices about birth control. 
In addition, new strategies are needed for alternative effective and cheaper methods of contraceptives to 















       6.0 EFFECT OF SEX HORMONES ON ADAPTIVE IMMUNE RESPONSES  
 
6.1 LITERATURE REVIEW 
The effect of sex steroid hormones on the immune responses to human TB infection remains less studied. 
Even though evidence of influence of sex hormones on immune functions have been shown in simple 
animal experiments involving castration and hormone replacement [44]. Literature relevant to this topic is 
discussed in Chapter 3, generally, progesterone and testosterone have been shown to play an 
immunosuppressive role in TB infection. In addition, progestin-based DMPA has been shown to affect 
control of mycobacterial infection and BCG-induced cytokine expression in mice studies [97], and is linked 
to increased risk of HIV acquisition, as described in the previous chapter. However effect of these hormones 
in human TB infection and, whether there is any synergistic effect in HIV and TB co-infection is unknown.   
 
AIMS 
a) To quantitate levels of progesterone, testosterone and DMPA in a cohort of HIV-infected 
females and males using LC-MS/MS. 
 
b) To determine their effects on adaptive immune responses to TB and HIV by: 
 
i) Evaluating changes in phenotype expression of T regulatory cell subsets, naïve and 
memory subsets as well as changes in activation and exhaustion of CD4 and CD8 T cells. 
 













6.2 MATERIALS AND METHODS 
6.2.1 Ethics statement 
Ethical approval for the Cryptococcal cohort study was obtained from the University of KwaZulu-Natal 
Medical Research Ethics Committee in Durban and Partners Healthcare’s Institutional Review Board in 
Boston.  
 
6.2.2 Study design 
The study design used for the Cryptococcal cohort study was cross sectional. Participants were initially 
recruited as part of a larger cohort for screening of cryptococcal meningitis at iThembalethu clinic in 
Durban. 271 participants, composed of 172 females and 99 males were randomly selected. All participants 
were HIV infected adults aged ≥18 years. Patients were recruited at time of initial HIV diagnosis, before 
initiation of antiretroviral therapy. Clinical and demographic data such HIV status, gender, contraceptive 
use, CD4 cell count were captured. All the study participants gave written informed consent. 
 
Table 6.1 Cohort characteristics 
 Total 
samples 
(n = 271) 


















male 99 18 – 65 31 11 - - 
female 172 19 - 58 31 11 3 3 
 
 
6.2.3 Screening tests 
HIV-1 testing was done at iThembalethu clinic in Umlazi Clinic before enrolment into the study. Spot and 
induced sputum samples were collected and active TB infection was confirmed by both positive Ziehl-




6.2.4 Specimen collection 
Blood was drawn into EDTA collection tubes. Plasma samples were collected after centrifugation of blood 
and PBMCs were isolated using the standard Ficoll gradient protocol. All samples (1ml plasma and 5million 
cells/ml) were stored at -800C and subsequently transferred into liquid nitrogen for long term storage. 
 
6.2.5 Measurement of sex hormones and contraceptive analogues in plasma using LC-
MS/MS 
 
Measurement of sex hormone and contraceptive levels was achieved using the method and materials 
described in Chapter 4. 
 
6.2.6 Preparation of peripheral blood mononuclear cells (PBMC) for intracellular cytokine 
staining (ICS) and immunophenotyping 
Frozen PBMC sample vials were thawed in a water bath at 370C until a small ice pellet was left. The vials 
were then disinfected with 70% ethanol and immediately transferred into the biosafety cabinet.  Vial 
contents were emptied into a 15ml Falcon tube with R10 media (8ml) containing DNase, to prevent 
clumping of cells. Media was topped-up to 10ml and cells were washed by centrifugation (Beckmann 
Coulter Allegra X) for 5minutes. Supernatant was discarded and cells were re-suspended in 10ml of R10 
media and counted using the T-C20 automated cell counter (Bio-Rad). For cell counting 10µl of cell 
suspension was mixed with 10µl of Trypan blue dye (Bio-Rad) and transferred into counting slides. Cells 
were then centrifuged and the pellet suspended in 4ml R10, without DNase. The cell suspension was 
transferred to 12-well culture plates and incubated at 370C, 5% CO2 for 4 hours. 
After a 4 hour incubation period, cells were transferred into a Falcon tube, centrifuged and re-suspended in 
R10 media such that, there were at least 500 000 cells per 200µl volume. Cells were then partitioned for 
immediate phenotype staining and for ICS. 
 
 
Immediate immunophenotype staining 
200ul volume containing at least 500 000 cells was transferred into a FACS tube and 1ml phosphine 
buffered saline (PBS) added. Cells were centrifuged and supernatant was discarded, blotting off extra 
supernatant on a clean paper towel. 25µl of surface stain master mix (prepared as indicated in table 6.2), 
was added to into each sample tube and incubated in the dark, at room temperature for 20 minutes. Cells 
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were washed with 1ml PBS twice, and 100µl of eBioscience fixation/permeabilization solution (prepared 
by mixing 1 part concentrate to 3 parts diluent) was added and incubated in the fridge, in the dark (40C) for 
20 minutes. Cells were removed from the fridge and washed with 1ml, 10X eBioscience buffer. Extra 
supernatant was blotted off and 25µl of intracellular stain master mix was added into each sample 
(preparation shown in table 6.2) and samples were incubated in the dark at room temperature for 20minutes. 
Cells were then washed once with the eBioscience buffer, re-suspended in 500µl of 2% paraformaldehyde 
(PFA), and stored at 4oC until ready for acquisition on Flow Cytometer. 
 
Intracellular cytokine staining 
Another portion of the cells were used in ICS. Approximately 180µl of cell suspension of each sample was 
transferred into a 96-well plate for 5 different stimulation conditions including non-stimulated control (table 
6.2). Different stimulatory antigens (purified protein derivative (PPD), staphylococcus enterotoxin B 
(SEB), cytomegalovirus peptide pool (pp65) as well as HIV peptide pool mixture (Gag, Pol, Env, Nef, Reg 
and Acc peptides) for general HIV response were added to their respective wells. 15µl CD107a antibody 
added was also added at this time and plate was incubated at 370C, 5% CO2 for 18 hours. Two hours into 
stimulation, 0.4µl Golgi stop and 0.4µl Golgi plug were added to each sample to block cytokine release 
from cells. After 18 hour stimulation, the plate was centrifuged and washed with PBS twice. 
Extra supernatant was blotted off and 25µl of surface stain master mix (prepared as indicated in table 1), 
was added to into each sample well and incubated in the dark, at room temperature for 20 minutes. Cells 
were washed with 200µl PBS twice, and 100µl of BD Cytofix/Cytoperm solution was added and incubated 
in the fridge, in the dark (40C) for 20 minutes. Cells were removed from the fridge and washed with 200µl, 
10X BD Perm/Wash buffer. Extra supernatant was blotted off and 25µl of intracellular stain master mix 
was added into each well (preparation shown in table 1) and samples were incubated in the dark at room 
temperature for 20minutes. Cells were then washed once with the 10X BD Perm/Wash buffer and cells re-
suspended in 500µl of 2% paraformaldehyde (PFA), transferred into FACS tubes and stored at 40C until 




6.2.7 Titration of antibodies to determine optimal concentration 
Antibodies were titrated to determine optimal working concentration for maximal staining of the CD4+ and 
CD8+ T cell populations with minimum background staining under the conditions of the experiment. Serial 
titrations of each antibody were used to stain PBMCs using protocol in section 6.2.6. The samples were 
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analyzed by flow cytometry to determine the concentration at which the sample is near, but not above, the 
saturation point (Table 6.2). 
 
Table 6.2. Antibody panel used for ICS and phenotype staining of PBMCs. 
INSTRUMENT                            BD LSR FORTESSA 
 Fluorochrome Optimal antibody 
dilution 
Vendor, Cat. No., Clone 
ICS panel    
Surface Antibody    
CD4 Alexa Fluor 700 1:100 BD Pharmingen, 557922, RPA-T4 
CD8 HV500 1:100 BD Horizon, 560774, RPA-T8 
CD14 APC-Cy7 1:50 BD Pharmingen, 557831, MΦP9 
CD16 BV650 1:50 Biolegend, 302042, 3G8 
CD56 BV711 1:50 Biolegend, 318336, HCD56 
CD19 APC-H7 1:50 BD Pharmingen, 560252, SJ25C1 
Live/Dead fixable near-
IR 
 1:200 Life Technologies, L10119 
    
Intracellular Antibody    
CD3 PE-CF594 1:100 BD Horizon, 562280, UCHT1 
TNFα PE-Cy7 1:25 Biolegend, 502930, Mab11 
IFNγ PerCP-Cy5.5 1:25 Biolegend, 502526,  4S.B3 
IL-2 PE 1:25 Biolegend, 500307, MQ1-17H12 
IL-13 V450 1:25 BD Horizon, 561158, JES10-5A2 
1L-17 BV605 1:40 Biolegend, 512326, BL168 
Mip-1β FITC 1:25 R&D Systems, IC271F, IgG2B 
CD107a CD107a 15µl BD Pharmingen, 555802 
    
Phenotype panel    
Surface Antibody    
CD38 PE-Cy7 1:25 Biolegend, 303516, HIT2 
PD-1 BV421 1:25 BD Horizon, 562516, EH12.1 
CD8 HV500 1:100 BD Horizon, 560774, RPA-T8 
CD161 BV605 1:50 Biolegend, 339916, HP-3G10 
CD4 BV711 1:50 Biolegend, 317440, OKT4 
CD25 BV785 1:50 Biolegend, 302637, BC96 
HLA-DR FITC 1:25 BD Pharmingen, 555560 
CD62L PE 1:50 Biolegend, 304806, DREG-56 
CCR7 PerCP-Cy5.5 1:50 Biolegend, 353220, G043H7 
CD127 PE-CF594 1:25 BD Horizon, 562397, HIL-7R-M21 
CD45RA Alexa Fluor 700 1:25 Biolegend, 304120, HI100 
CD14 APC-Cy7 1:50 BD Pharmingen, 557831, MΦP9 
CD19 APC-H7 1:50 BD Pharmingen, 560252, SJ25C1 
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L/D fixable near-IR  1:200 Life Technologies, L10119 
    
Intracellular Antibody    
CD3 eFluor 650 1:100 eBioscience, 95-0037-42, OKT3 
FoxP3 APC 1:10 eBioscience, 17-4776-41, PCH101 
 
 
6.2.8 Flow cytometry analysis 
Calibration of flow cytometer 
In flow cytometry, fluorochromes have different emission spectra, however when using a multi-color panel 
(such as 15-color used in this study), it requires good compensation as different fluorochromes tend to 
spillover. Compensation allows for correction of spillover by quantifying and subtracting the amount by 
which each fluorochrome overlaps into another.  For this study, a compensation beads kit containing BD 
negative control beads which have no antibody-binding capacity, BD IgK mouse compensation beads 
which bind to antibodies was used. To set-up the 15-color panel compensation, 16 tubes were prepared by 
adding a drop of negative and positive control beads into each tube. Fifteen tubes were each added with a 
specific antibody with the following fluorochromes: FITC/Alexa Fluor 488, PE, PerCP-Cy5.5, PE-Cy5, 
PE-Cy7, APC-Cy7, APC, BV421, BV711, BV785,BV650, BV605, PE- Texas Red, Alexa Fluor 700, 
HV500, and one of the tubes, a negative control was left unstained. The tubes were then incubated for 30 
minutes, washed and PBS added. Acquisition was done on the LSR BDFortessa using FACSDiva Software 
version 7.0. Positive and negative population gates for each fluorochrome were set, while adjusting the 
PMT values to reduce emission spectral overlap. Compensation was calculated and overlap of below 50% 
between any two fluorochromes was acceptable. The compensation settings were used in all further 
analysis. BD rainbow fluorescent particles were used for each acquisition thereafter, to monitor 
instrumental day-to-day variation. All settings for the flow cytometer were based on instrument laser 




The BD FACSDiva software version 7.0 was used for creation of the acquisition template with the scatter 
plots forward scatter (FSC) vs. side scatter (SSC) used to define lymphocyte populations. The subsequent 
gating strategies that were used to for analysis of lymphocyte subsets are shown in the results section of 




Table 6.3. Flow cytometer instrument settings.  
Instrument                            BD LSR FORTESSA 
Fluorochrome Laser (wavelength) Emission Filter 
PerCP-Cy5.5 Blue (488nm) 695/40 
FITC/Alexa Fluor 488  530/30 
APC-Cy7 /APC-H7 Red (640nm) 780/60 
Alexa Fluor 700  730/45 
APC  670/30 
BV785/ QDot800 Violet (405nm) 780/60 
BV711/ QDot705  710/50 
BV650/ QDot655  670/30 
BV605/ QDot605  610/20 
 HV500  525/50 
BV421/ PacBlue  450/50 
PE-Cy7 Yellow-Green (561nm) 780/60 
PE-Cy5  670/30 
PE- Texas Red/ PE-CF594   610/20 
PE  585/15 
 
6.2.9 Materials 
Table 6.4 List of materials and reagents used in the methods described above. 
Reagents and Materials Product No., Supplier 
RPMI 1640, without L-Glutamine Lonza, BE12-167F 
Pen-Strep Lonza, DE17-602F 
L-Glutamine Lonza, BE17-605F 
Tuberculin PPD Statens Serum Institut, 2391 
Phosphate buffered saline (PBS) tablets Sigma-Aldrich, P4417-100TAB 
BD Perm/Wash buffer 10x BD Biosciences, 51-2091KZ 
BD Cytofix/Cytoperm BD Biosciences, 51-2090KZ 
Fixation/Permeabilization diluent eBioscience, 00-5223-56 
Permeabilization buffer 10x eBioscience, 00-8333-56 
Compensation beads kit (Anti-mouse Ig-κ/ 
Negative control) 
BD Biosciences, 552843 
Rainbow fluorescent particles (mid-range FL1 
fluorescence 
BD Biosciences, 556298 
FACS clean BD Biosciences, 340345 
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FACS rinse BD Biosciences, 340346 
Staphylococcal enterotoxin B (SEB) Sigma Aldrich, S4881-1MG 
pp65 cytomegalovirus peptide (CMV) Donation from HIV Pathogenesis Programme 
HIV peptides (Gag, Pol, Env, Nef, Acc, Reg)  Donation from HIV Pathogenesis Programme  
50ml Falcon  polypropylene tubes Corning, 352070 
15ml Falcon  polypropylene tubes Corning, 352096 
5ml Falcon  polystyrene tubes Corning, 352054 
Golgi stop BD Biosciences, 554724 
Golgi plug BD Biosciences, 555029 
 
6.3 STATISTICAL ANALYSES 
 
Data for quantitation of sex hormones was analysed using Analyst software version 1.6 and Graph Pad 
Prism version 6. Flow cytometry data was analysed using FlowJo version 9.8 and Graph Pad Prism version 
6. Mann-Whitney tests were used to compare median values between two groups. Pearson’s correlation 
was used to determine correlation between DMPA and progesterone. Kruskal-Wallis tests were used for 
comparisons with more than two independent variables and the Bonferroni and Dunn’s tests, used for 
multiple comparisons. P values ≤ 0.05 were considered significant. 
 
6.4 RESULTS  
6.3.1 Mass spectrometry 
All 271 patient plasma samples were processed and analysed using mass spectrometry. The method 
provided information on progesterone, testosterone and DMPA concentration levels on both males and 
females (Figure 6.1). 
 
Progesterone concentrations amongst females clustered into two groups (Figure 6.1A), with some females 
in the low group having concentrations below the limit of quantification (LOQ). Generally, females had 
significantly higher progesterone levels than males as expected (p = 0.0014). Most males had progesterone 
levels near or below the LOQ. However, three reported male participants had significant levels of 
progesterone, comparable to the group of women with highest progesterone levels. 
 
The method also positively identified patients using the injectable contraceptive Depo-Provera, and 
informed the levels of DMPA in their plasma (Figure 6.1B). All male patients had no DMPA in their 
67 
 
plasma, indicated by levels below the LOD and LOQ. Females plasma DMPA concentrations, on the other 
hand, revealed two groups of females with significant  DMPA (above LOQ) and non-significant or no  
DMPA (below LOQ). Correlation plot of DMPA and progesterone levels in females (Figure 6.1D), revealed 
three clusters or groups with i) high DMPA, low progesterone, ii) no DMPA, low progesterone and iii) no 
DMPA, high progesterone. This was a significant negative correlation (p = 0.0016, Pearson r = -0.2446). 
 
Plasma testosterone concentrations (Figure 6.1C), were significantly higher in males than females, as 
expected (p < 0.0001). However there were some outliers, either males with very low or females with very 
high testosterone levels. 
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Figure 6.1 Quantification of sex hormones in male and female plasma samples. We illustrate differences 
in A) progesterone, B) DMPA and C) testosterone levels between males and females. D) Correlation of 
progesterone and DMPA levels in females (Pearson correlation). Mann-Whitney test was used to compare 




6.3.2 Patient selection for flow cytometry  
All 271 patient plasma samples were used for quantitation of progesterone, testosterone and DMPA. For 
flow cytometry analysis however, specific groups that would allow us to determine if there were any 
differences in immune responses as a result of differences in natural hormones levels, differences in 
contraceptive status, or disease status, were selected from the mass spectrometry data. For females, four 
groups were selected, one group consisted of 11 patients with active TB disease (culture positive) and from 
the mass spectrometry data, because of the huge spread in data and in order to see maximum effect if there 
were any differences at all, we selected two groups with highest progesterone and lowest progesterone 
levels and were not using injectable contraceptive DMPA. The fourth group were individuals who had 
DMPA levels above the LOQ, and these patients were selected randomly. For males, we had three groups; 
11 individuals with active TB disease and from the mass spectrometry data, two groups were selected with 
highest and lowest testosterone levels. 
 




Figure 6.2 Gating strategy. Lymphocyte populations were defined using the SSC-A (side scatter-A) against 
FSC-A (forward scatter-A). Doublets were excluded by gating on forward scatter-height (FSC-H) against 
FSC-A.  A dump channel was used to gate on live cells, while excluding CD14, CD19 expressing 
lymphocytes and dead cells. CD3+ lymphocytes were selected by gating on SSCA against CD3. CD3+ T 
cells were further gated into CD4+ and CD8+ T cell subsets. 
 
6.3.4 Expression of activation and exhaustion markers, CD38, HLA-DR and PD-1 
 
 
Figure 6.3 Representative illustration of expression of CD38, HLA-DR and PD-1 in CD4+ and CD8+ T 








Figure 6.4 Expression of CD38, HLA-DR and PD-1 in both CD4 and CD8 T cells in female subgroups 
with high progesterone, low progesterone and DMPA positive. Mann-Whitney test was used to compare 
the groups. Horizontal lines on graphs represents the median. P-values < 0.05 were considered significant. 
 
To examine if differences in progesterone levels and DMPA use had an effect on activation and/or 
exhaustion of CD4 and CD8 T cells, unpaired non-parametric T tests (Mann-Whitney tests) were used to 
compare the different groups in Figure 6.4. There were no significant difference in expression of activation 
markers, CD38 and HLA-DR or exhaustion marker, PD-1. However, a general trend of lower CD38 
expression in CD4 and CD8 and lower PD-1 in CD8 T cells amongst female with high progesterone levels 
compared with the other two groups was observed. DMPA positive and low progesterone groups had 
comparable CD38 and PD-1 expression for both CD4 and CD8 T cells and PD-1 was, generally, more 
expressed in CD4 T cells from high progesterone group. Similar to the female subgroups, there were no 
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significant differences in expression of CD38, HLA-DR and PD-1 between high and low testosterone male 
subgroups (Figure 6.5). 
 
 
Figure 6.5 Expression of CD38, HLA-DR and PD-1 in both CD4 and CD8 T cells in high and low 
testosterone male groups. Mann-Whitney test was used to compare the groups. Horizontal lines on graphs 
represents the median. P-values < 0.05 were considered significant. 
 
6.3.5 Differences in T regulatory subsets 
 
Figure 6.6 FoxP3 expression of CD4 T cells in high progesterone, low progesterone and DMPA positive 
groups. Mann-Whitney test was used to compare the groups. Horizontal lines on graphs represents the 






Figure 6.7 Expression of FoxP3+CD25+ and FoxP3+CD25+CD127-/lo CD4 T regulatory cells in high 
progesterone, low progesterone and DMPA positive groups. Mann-Whitney test was used to compare the 
groups. Horizontal lines on graphs represents the median. P-values < 0.05 were considered significant. 
 
 
The effect of differences in progesterone, testosterone and DMPA use on T regulatory cells were analysed. 
There were no significant differences in expression of FoxP3 in CD4 T cells (Figure 6.6), or in percentage 
of CD4+Foxp3+CD25+ T cells (Figure 6.7), in females with high and low progesterone levels as well as 
DMPA positive groups. Significantly higher expression of CD4+FoxP3+CD127-/loCD25+ cells were 
observed in females with high progesterone levels compared to those with low levels (p = 0.0052) In 
general, the high progesterone group had higher expression of T regulatory subsets compared with low 
progesterone and DMPA positive groups, whereas the latter groups had comparable expression of these cell 
subsets. 
There was no significant difference in T regulatory subsets between high testosterone males and low 




Figure 6.8 Comparison of Foxp3+CD4+ T regulatory subset expression between high and low testosterone 
males. . Mann-Whitney test was used to compare the groups. Horizontal lines on graphs represents the 
median. P-values < 0.05 were considered significant. 
 
 
6.3.4 Differences in expression of naïve and memory T cell subsets 
 
Figure 6.9 Gating naïve and memory T cell subsets, using CCR7 and CD45RA expression. I. Naïve T cells. 
II. Central memory T cells. III. Effector memory T cells. IV. Terminally differentiated effector memory T 
cells. 
Memory and naïve T cell subsets were defined by expression of CCR7 and CD45RA (Figure 6.9). No 
significant differences in naïve and memory CD4 and CD8 T cells, were observed between high and low 
progesterone as well as DMPA positive and low progesterone female groups. DMPA positive females had 
significantly higher expression of CD45RA+CCR7+ (naïve) and CD45RA+CCR7- (terminally 
differentiated effector memory) CD4 T cells compared with high progesterone group, with p values of 
0.0436 and 0.0343 respectively (Fig 6.10). CD45RA+CCR7- subset was also significantly expressed in 
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CD8 T cells of DMPA positive group (p = 0.0153), while high progesterone significantly expressed the 
central memory subset (p = 0.053), as shown in Figure 6.11. 
 
 
Figure 6.10 Comparison of CD45RA and CCR7 expression as a percentage of CD4 T cells in DMPA 
positive and high progesterone females. Temra represents terminally differentiated effector memory T cells.  
Mann-Whitney test was used to compare the groups. Horizontal lines on graphs represents the median. P-





Figure 6.11 Comparison of CD45RA and CCR7 expression as a percentage of CD8 T cells in DMPA 
contraceptive users and high progesterone females. Temra represents terminally differentiated effector 
memory T cells.  Mann-Whitney test was used to compare the groups. Horizontal lines on graphs represents 
the median. P-values < 0.05 were considered significant. 
 
Expression of CD45RA and CCR7 was also analysed in high and low testosterone males. In the CD4 T 
cells, no significant differences were seen naïve and memory subsets. In CD8 T cells however, males with 
high levels of testosterone had a higher expression of CD45RA+CCR7+ and CD45RA-CCR7+, with p = 
0.0590 for both subsets. Males with low testosterone had significantly higher expression of 




Figure 6.12 Comparison of CD45RA and CCR7 expression as a percentage of CD8 T cells in high and low 
testosterone males. Temra represents terminally differentiated effector memory T cells. Mann-Whitney test 




6.3.5 Effect of sex hormones on CD4 and CD8 T cell cytokine expression 
 
We next investigated the effect of sex hormones on antigen- specific immune responses of CD4+ and CD8+ 
T cells. To do this, PBMCs were stimulated with SEB (positive control), PPD, CMV, and HIV peptide 
pools over 18 hours. An unstimulated sample (negative control) was set-up for each sample for fluorescence 
background subtraction (Figure 6.13).  We first compared differences in expression of immunological 
factors, TNFα, IFNγ, IL-2, IL-17, Mip-1β and CD107a, between high progesterone, low progesterone and 





Figure 6.13 PBMCs were stimulated with SEB, PPD, CMV and HIV peptides and flow cytometry was 
used to determine antigen-specific CD4+ and CD8+ T cells expressing TNFα, IFNγ, IL-2, IL-17, Mip-1β 
and CD107a. Antigen-specific T cell responses were defined by subtracting background signal in the 





Figure 6.14 Expression of TNFα, IFNγ, IL-2, IL-17, Mip-1β and CD107a as frequency of parent 
population CD4+ T cells in SEB stimulated PBMCs. Multiple comparisons using the Kruskal-Wallis test 
was used to compare the groups. Horizontal lines on graphs represents the median. P-values < 0.05 were 
considered significant. 
 
Analysis using the Kruskal-Wallis tests and Dunn’s multiple comparisons, showed no significant 
differences observed in CD4 expression of TNFα, IFNγ, IL-2, IL-17, Mip-1β or CD107a upon 
stimulation with SEB (Figure 6.14), PPD, CMV and HIV (Appendix). Using Mann-Whitney tests for 
comparison between two groups at a time, also showed no significant differences in any of the cytokines, 
except for increased IL-2 expression  in high progesterone compared to low progesterone (Figure 6.15),in 
CD4 T cells stimulated with SEB, (p = 0.0399). However, generally, CD4 expression of TNFα, IFNγ, IL-
2, and Mip-1β responses was increased in high progesterone group compared to both low progesterone and 
DMPA positive groups. Comparison between high testosterone males and low testosterone showed no 






Figure 6.15 High progesterone group shows increased CD4 T cell cytokine expression compared to 
DMPA positive and low progesterone groups. An example showing expression of IL-2 and Mip-1β as 
frequency of parent population CD4+ T cells stimulated with SEB (A) and PPD (B). Mann-Whitney test 
was used to compare the groups. Horizontal lines on graphs represents the median. P-values < 0.05 were 
considered significant. 
 
The same general trend was observed in CD8 T cell cytokine expression.  High progesterone group showed 
increased expression of IFNγ (p = 0.0310), TNFα, and IL-2 when compared to DMPA positive group 
(Figure 6.16). Also, in response to HIV stimulation, this group expressed significantly higher levels of 





Figure 6.16 High progesterone group shows increased CD8 T cell cytokine expression compared to 
DMPA positive and low progesterone groups. An example showing expression of TNFα, IFNγ and IL-2 
as frequency of parent population CD8+ T cells stimulated with SEB (A).Mann-Whitney test was used to 
compare the groups. Horizontal lines on graphs represents the median. P-values < 0.05 were considered 
significant. 
 
To determine differences in immune responses between males and female, with and without TB disease, 
comparisons were done using Kruskal Wallis tests and multiple comparisons and showed no significant 
differences between the groups, for example Figure 6.17. Using Mann-Whitney tests, we compared males 











Figure 6.17 Expression of TNFα, IFNγ, IL-2, IL-17, Mip-1β and CD107a in PPD stimulated cells, as 
frequency of parent population CD4+ T cells. Multiple comparisons using the Kruskal-Wallis test was used 
to compare between male and females, with or without TB. Horizontal lines on graphs represents the 
median. P-values < 0.05 were considered significant. 
 
6.4 DISCUSSION 
In this chapter, we demonstrate the application of an LC-MS/MS method for quantitation of endogenous 
sex hormones and hormonal contraceptive DMPA. As previously described in chapter 5, LC-MS/MS 
analysis of sex hormones has gained attention in recent years owing to the high sensitivity and specificity 
of the technique. Using this method, we were able to quantify levels of progesterone, testosterone and 
DMPA on plasma samples from HIV-infected males and females.  
Progesterone levels in females vary with the menstrual cycle, but generally, two phases occur, that is, the 
pre-ovulatory phase when progesterone levels are low, known as the follicular phase and post-ovulation 
when progesterone levels rapidly rise in preparation for pregnancy, the luteal phase. Analysis of 
progesterone levels in females clustered into two groups with high and low progesterone, suggesting luteal 
and follicular phases respectively. Male progesterone levels, are generally known to be in the low picomolar 
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range, and we observed low progesterone levels in males, near or below the limit of quantification however 
three outliers had significantly higher progesterone which may suggest misreporting of gender in the study 
or possibly males with XXY genotype.   
Only three participants of the 196 females selected for this study reported to be using the injectable 
contraceptive DMPA. Our analysis however, found 42 patient samples to have DMPA levels higher than 
the limit of quantification. A possible explanation for this observation maybe misreporting by patients or 
alternatively, since DMPA is a slow-release long acting injectable contraception, patients will have different 
retention periods of the contraceptive and it remains in the circulatory system for longer after its 
administration is stopped. This may mean that even though patients are no longer using DMPA, significant 
levels of the contraceptive can still be detected and quantified in their plasma. As described in chapter 5, 
DMPA acts as a suppressor of progesterone and the same negative correlation between progesterone and 
DMPA levels was observed in this study. Also testosterone levels in both males and female were quantified, 
and generally men had significantly higher testosterone levels than women as expected. However, some 
males had very low testosterone levels while some females had high testosterone, which maybe indicate 
androgen deficiency in males, misreporting of gender in the study or XYY and XXY genotypes. 
Many previous studies studying effects of sex hormones on immune responses, using animal models, 
particularly involving castration or ovariectomization of males and females, followed by hormone 
supplementation have suggested a role for these hormones in susceptibility to TB. We therefore set to 
investigate the effects varying levels of endogenous sex hormones on CD4 and CD8 T cells phenotypes as 
well as T cell cytokine production. Patients with highest and lowest progesterone and testosterone levels in 
females and males, respectively, were selected to analyze this effect. Injectable contraception, DMPA 
positive individuals were used to compare the effect of synthetic progestin on the immune response.  
Effects of sex hormones and hormonal contraception on cellular activation, remains less studied in HIV 
[88] and TB as well. Expression of activation markers CD38, HLA-DR and exhaustion marker PD-1 was 
analysed. We observed no significant differences in either activation or exhaustion of both CD4 and CD8 
T cells. However females with naturally low progesterone or induced low progesterone (DMPA positive 
group) generally showed higher CD38 expression in both CD4 and CD8 T cells. In the context of HIV 
infection, the FRESH study shows that hormonal contraception seems to be associated with activation of 
CCR5+CD4+ T cells, in the cervix and not blood. Which may suggest a possible mechanism for increased 
risk of HIV, as this CCR5+CD4+ phenotype is known to be target cells for HIV. 
 Analysis of T regulatory cells, defined using FoxP3, CD25 and CD127, also revealed no significant 
differences. We also investigated differences in naïve and memory T cell subsets. These T cell subsets have 
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been well characterized before, using a number of markers including CCR7and CD45RA [99, 100], as 
shown in Figure 6.7. In this study we observed no significant differences in CD4+ naïve and memory 
populations between males with high and low testosterone, as well as CD4+ and CD8+ populations between 
females with high progesterone and low progesterone or DMPA positive and low progesterone. The small 
number of sample used for these comparisons, may not be able to show any significant effect, if any is 
present However, high progesterone females showed significantly higher expression of central memory and 
terminally differentiated memory CD4 and CD8 subsets compared to DMPA positive group, an observation 
also seen in CD8 subsets of high testosterone males compared to low testosterone. With lack of previous 
evidence studies investigating effect sex hormones on these cells, with regard to TB and HIV, it is difficult 
to conclude what these observations mean. Further investigations, with larger sample size may be needed 
to confirm these observations.  
 
We also investigated antigenic stimulation of CD4 and CD8 T cell responses, to determine differences in 
cytokine expression. We observed no significant differences in cytokine production, however found a trend 
towards higher production of TNFα, IFNγ, IL-2,  Mip1β and CD107a by females with high progesterone 
levels compared to DMPA positive group and low progesterone group, in CD4 and CD8 T cells. Low 
numbers of patients in each group may possibly mean this analysis was under powered to observe any 
significant effect, however if this trend can be confirmed, it would be in line with the literature as DMPA 













CHAPTER 7: GENERAL CONCLUSION 
The significant influence of sexual inequality observed between males and females in susceptibility to, and 
severity of infectious diseases need to be considered in development of therapeutic interventions against 
diseases. Tuberculosis, is no exception to this observed sex-based bias. Understanding factors that 
predispose males to increased susceptibility is key, and sex hormones have been suggested as one of the 
biological factors that play a role in this observed bias in TB incidence. In addition, changes in hormones 
during the menstrual cycle, and use of DMPA have been linked to increased risk of HIV. Therefore this 
study aimed at quantitation of sex hormones and injectable contraceptive, DMPA with the particular aim 
of evaluating relationship with immune responses to TB and HIV. 
A highly specific method using LC-MS/MS method was developed and allowed for identification and 
quantification of sex hormones in study patients. A key observation was misreporting, in particular by 
female participants with regard to contraceptive use. This large under-reporting of contraceptive use 
indicates the value in direct measurement as opposed to self-reporting. The ability to clearly distinguish 
different phases of menstrual cycle, informed by progesterone levels detected, allows us to study hormonal 
changes and how they may impact immune responses to TB and HIV. 
A clear relationship between injectable contraceptive use and risk of HIV acquisition is shown in the 
FRESH cohort. The presence of activated CCR5+C4+ HIV target cells in the cervix of injectable 
contraceptive users, may suggest a mechanism for increased susceptibility to HIV. Study of mucosal 
changes in the cervical region reveals proteins which are differentially expressed in DMPA and non-DMPA 
users. This preliminary data shows downregulation of certain proteins which are important in protection of 
the FRT against infections and in particular HIV. This data may suggest that DMPA changes the 
environment in the FRT to increase susceptibility to HIV. 
In this study, generally, there were no significant effects of hormonal differences in immune responses. A 
limitation to this study is the sample size, therefore further work will have to involve more study patients 
to investigate if the effect of sex hormones levels on immune responses to TB and HIV observed in animal 
studies is seen in humans. Finally, the increased risk associated with DMPA is an important finding that 
should inform development of alternative contraceptive strategies for women, especially in developing 
countries where DMPA is used the most. Also women, should at least be warned on the effects of this 
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Appendix 2: Expression of TNFα, IFNγ, IL-2, IL-17, Mip-1β and CD107a as frequency of parent 
population CD4+ T cells in CMV stimulated PBMCs. Multiple comparisons using the Kruskal-Wallis 
test was used to compare the groups. Horizontal lines on graphs represents the median. P-values < 0.05 












Appendix 3: Expression of TNFα, IFNγ, IL-2, IL-17, Mip-1β and CD107a as frequency of parent 
population CD4+ T cells in HIV stimulated PBMCs. Multiple comparisons using the Kruskal-Wallis test 















Appendix 4: Expression of TNFα, IFNγ, IL-2, IL-17, Mip-1β and CD107a as frequency of parent 
population CD4+ T cells in PPD stimulated PBMCs. Multiple comparisons using the Kruskal-Wallis test 
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Association between injectable progestin-only 
contraceptives and HIV acquisition and HIV target cell 
frequency in the female genital tract in South African 
women: a prospective cohort study
Elizabeth H Byrne*, Melis N Anahtar*, Kathleen E Cohen, Amber Moodley, Nikita Padavattan, Nasreen Ismail, Brittany A Bowman, 
Gregory S Olson, Amanda Mabhula, Alasdair Leslie, Thumbi Ndung’u, Bruce D Walker, Musie S Ghebremichael, Krista L Dong, Douglas S Kwon
Summary
Background The use of injectable progestin-only contraceptives has been associated with increased risk of HIV 
acquisition in observational studies, but the biological mechanisms of this risk remain poorly understood. We aimed 
to assess the eff ects of progestins on HIV acquisition risk and the immune environment in the female genital tract.
Methods In this prospective cohort, we enrolled HIV-negative South African women aged 18–23 years who were not 
pregnant and were living in Umlazi, South Africa from the Females Rising through Education, Support, and Health 
(FRESH) study. We tested for HIV-1 twice per week to monitor incident infection. Every 3 months, we collected 
demographic and behavioural data in addition to blood and cervical samples. The study objective was to characterise 
host immune determinants of HIV acquisition risk, including those associated with injectable progestin-only 
contraceptive use. Hazard ratios (HRs) were estimated using Cox proportional hazards methods.
Findings Between Nov 19, 2012, and May 31, 2015, we characterised 432 HIV-uninfected South African women from 
the FRESH study. In this cohort, 152 women used injectable progestin-only contraceptives, 43 used other forms of 
contraception, and 222 women used no method of long-term contraception. Women using injectable progestin-only 
contraceptives were at substantially higher risk of acquiring HIV (12·06 per 100 person-years, 95% CI 6·41–20·63) 
than women using no long-term contraception (3·71 per 100 person-years, 1·36–8·07; adjusted hazard ratio [aHR] 
2·93, 95% CI 1·09–7·868, p=0·0326). HIV-negative injectable progestin-only contraceptive users had 3·92 times the 
frequency of cervical HIV target cells (CCR5+ CD4 T cells) compared with women using no long-term contraceptive 
(p=0·0241). Women using no long-term contraceptive in the luteal phase of the menstrual cycle also had a 3·25 times 
higher frequency of cervical target cells compared with those in the follicular phase (p=0·0488), suggesting that a 
naturally high progestin state had similar immunological eff ects to injectable progestin-only contraceptives.
Interpretation Injectable progestin-only contraceptive use and high endogenous progesterone are both associated with 
increased frequency of activated HIV targets cells at the cervix, the site of initial HIV entry in most women, providing 
a possible biological mechanism underlying increased HIV acquisition in women with high progestin exposure.
Funding The Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases.
Introduction
Hormonal contraceptives have empowered women to 
prevent unwanted pregnancies since being introduced in 
the 1960s. Unlike condoms, hormonal contraceptives do 
not need the cooperation of the male partner, can be taken 
discreetly, and are available in longacting formulations that 
are more than 99% eff ective. Injectable progestin-only 
contraceptives, including depot medroxy progesterone 
acetate (DMPA) and norethindrone enanthate (NET-EN), 
are the favoured form of con traception in sub-Saharan 
Africa, where they are used by more than 8 million women.1 
Unfortunately, injectable progestin-only contraceptives do 
not provide protection against sexually transmitted 
infections and have been associated with a substantially 
increased risk of acquiring HIV in most but not all studies.2–5
In areas with both widespread injectable progestin-
only contraceptive use and high HIV incidence, 
including many regions in sub-Saharan Africa, the 
questions of whether and how injectable progestin-only 
contraceptives aff ect HIV acquisition risk are of utmost 
importance. Decisions regarding the use of injectable 
progestin-only contraceptives must carefully balance 
the risk of HIV acquisition with that of unwanted 
pregnancy. The epidemiological studies driving these 
decisions are complicated by behavioural and 
demographic con founders that might mask the 
biological eff ect of injectable progestin-only con-
traceptives on HIV acquisition.6 Studies of the 
association between HIV acquisition and injectable 
progestin-only contraceptives use have not reached 
consistent conclusions, and although progestins have 
been shown to have a multitude of eff ects on immune 
function in vitro,7–10 whether these eff ects are manifest 
in vivo is unclear.11,12
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We designed a prospective study and secondarily 
assessed the eff ects of progestins on HIV acquisition risk 
and the immune environment in the female genital tract, 
hypothesising that there is a biological mediator of the 
increased risk of HIV acquisition often observed in 
injectable progestin-only contraceptive users.
Methods
Study cohort and participants
HIV-negative women aged 18–23 years were recruited for 
the Females Rising through Education, Support, and 
Health (FRESH) study,13 an observational, prospective 
cohort study in Umlazi, South Africa (appendix). 
Participants were recruited by referral from three to four 
community organisations in Umlazi, South Africa, and 
community outreach events. We included women aged 
18–23 years residing in Umlazi, South Africa, who were 
able to understand the information and consent forms, 
willing to adhere to study requirements, and willing to 
give voluntary consent for participation. We excluded 
individuals with unknown HIV status and unwilling to 
have HIV tests done; unwilling to consent to blood 
storage; enrolled in any other study that involves frequent 
blood sampling or might otherwise interfere with this 
study; with any conditions or confl ict that is likely to 
prevent adherence to the study protocol and that might 
interfere with the outcome of the study, particularly 
adherence to the follow-up schedule, such as low 
likelihood to stay in or near Umlazi in the next 2–4 years 
or a chronic condition that requires regular blood 
sampling; pregnancy; and haemoglobin concentrations of 
less than 10 g/dL. The study protocol was approved by all 
local regulatory bodies (appendix). All participants 
provided written informed consent.
Procedures
Twice per week, participants attended classes focused on 
personal empowerment, job skills training, and HIV 
prevention, and had a fi nger prick blood draw for HIV 
RNA testing. Participants had a pelvic exam, phlebotomy, 
and completed a counsellor-administered HIV risk 
questionnaire every 3 months. The questionnaire asked 
participants whether they were using a family planning 
method, which method they were using, for how long 
they had been using that method, and whether they had 
a change in family planning method in the past 3 months. 
The questionnaire also addressed condom use and sexual 
behaviour. Study follow-up ranged from 3 months to 
24 months. One nurse did all of the pelvic exams, during 
which endocervical cells were collected using a cytobrush 
Research in context
Evidence before this study
We searched PubMed for articles published before July 7, 2015, 
using the search terms “depo provera” OR “dmpa” OR 
“nur isterate” OR “net-en” AND “HIV” and read those written in 
English. We examined relevant citations from the results of our 
search and identifi ed studies that examined HIV acquisition and 
contraceptive use from an epidemiological perspective, with 
some, but not all, reporting a signifi cant association. We also 
identifi ed studies that assessed the eff ect of progestins on the 
function of immune cells in vitro, in animal models, in ex-vivo 
tissue, or in blood or assessed cohorts not at high risk of HIV 
acquisition. Some studies examined the biological associations 
with contraceptive use in high-risk cohorts but limited their 
observations to soluble immune mediators and did not fi nd a 
concomitant increase in HIV acquisition risk.
Added value of this study
Previous studies examining the epidemiological risk of injectable 
progestin-only contraceptive use and HIV acquisition have 
variably been confounded by diff erences in behavioural risk 
factors reported between those using no long-term contraceptive 
and injectable progestin-only contraceptive users. These 
confounders might have masked potential biological eff ects of 
injectable progestin-only contraceptive use. Our study 
characterises a unique cohort of young women in which profi les 
of HIV risk factors had similar proportions across the cohort, so 
women using injectable progestin-only contraceptives and 
women using no hormonal contraception were similar in terms 
of HIV risk factors.
In this study, we identifi ed an increased frequency of HIV target 
cells at the cervix of HIV-negative women using injectable 
progestin-only contraceptives and, in the same group of 
women, noted a signifi cantly higher incidence of HIV 
acquisition in injectable progestin-only contraceptive users. We 
noted a similar pattern in HIV target cell frequency in the 
naturally high progestin state of the luteal phase in women not 
using long-term contraceptive, suggesting that progestins, 
both endogenous and exogenous, might be key mediators of 
target cell availability. Our work links epidemiological 
observations of HIV infection to the immunological eff ects of 
injectable progestin-only contraceptive use in the female 
genital tract and provides new mechanistic insight into the role 
of progestins in HIV acquisition risk in women.
Implications of all the available evidence
Our results, taken together with other studies, have cast further 
doubt about the safety of injectable progestin-only 
contraceptive in areas of high HIV incidence. Moreover, by 
concluding that a high progestin concentration, both in 
naturally cycling women and in injectable progestin-only 
contraceptive users, correlates with increased target cell 
availability at the cervix, we suggest that progestins might 
induce increased cervical HIV target cell frequency. This work 
provides new insight into the role of progestins in the female 
genital tract and might inform the development of biological 
prophylactics to reduce HIV acquisition for women. 
See Online for appendix
Downloaded from ClinicalKey.com at BS - University of Copenhagen March 31, 2016.
For personal use only. No other uses without permission. Copyright ©2016. Elsevier Inc. All rights reserved.
Articles
www.thelancet.com/infection   Vol 16   April 2016 443
(appendix). Samples were processed as described 
previously.13 Peripheral blood mononuclear cells were 
isolated from blood using a Ficoll gradient.
Consensus injectable progestin-only contraceptive use 
(appendix) was the primary covariate on which the 
primary analyses were based. Patient characteristics, high 
risk behaviour, and sexually transmitted infection status, 
assessed at the most recent follow-up, were also taken 
into account.
To detect sexually transmitted infections, HIV screening 
was done with HIV RNA PCR (Global  Laboratories, 
Durban, South Africa), and positive results were repeated 
for confi rmation. We tested for Neisseria gonorrhoeae, 
Chlamydia trachomatis, Trichomonas vaginalis, HSV-1, and 
HSV-2 with a posterior fornix swab (appendix).
Plasma progesterone and oestradiol concentrations 
were measured by the Massachusetts General Hospital 
Clinical Laboratory Research Core using chem ilumi-
nescent microparticle immunoassays (Abbott Labor-
atories, Diagnostics Division, IL, USA). Progesterone 
values below the limit of detection (0·1 ng/mL) were 
read as half the minimum limit of detection (ie, 
0·05 ng/mL). Oestradiol values below the limit of 
detection (10 pg/mL) were read as half the minimum 
limit of detection (ie, 5 pg/mL). Naturally cycling women 
were determined to be in the follicular or luteal phase of 
the menstrual cycle on the basis of their plasma 
progesterone concentration (follicular: progesterone 
≤0·3 ng/mL or luteal: pro gesterone ≥1·2 ng/mL).
Cervical and peripheral blood cells were stained with 
titrated monoclonal antibodies (appendix) and analysed 
with FACS ARIA III or LSRFortessa (BD Biosciences, 
San Jose, CA, USA) and FlowJo software (TreeStar, 
Ashland, OR, USA), as described previously.13
An important determinant of HIV acquisition risk is 
the frequency of HIV target cells at the mucosal site of 
exposure in the female genital tract.14–16 To test the 
hypothesis that injectable progestin-only contraceptives 
increase target cell frequency at the superfi cial layers of 
the cervix, we did fl ow cytometric analysis on freshly 
collected matched cervical cells and peripheral blood. 
Because injectable progestin-only contraceptives aff ect 
endogenous hormone concentrations (appendix) and 
endogenous progesterone might aff ect immune function, 
we controlled for plasma progesterone con centrations; 
we analysed samples in which plasma progesterone 
concentration was at most 0·3 ng/mL. We assessed the 
concentration of 14 soluble cytokines in cervicovaginal 
lavage and the cervicovaginal microbiome, as described 
previously.13 Medroxy progesterone acetate concentration 
was measured in plasma as described previously17 and in 
the appendix.
Outcomes
The aims of our primary cohort study were identifi cation 
and characterisation of host immune response and viral 
dynamics in acute HIV-1 infections. The secondary aims 
of our study included assessment of biological and 
behavioural correlates of HIV acquisition. Time to HIV-1 
infection was defi ned as the time from enrolment to the 
fi rst confi rmed positive HIV RNA PCR result, or censored 
at the last day of contact. Assessment of HIV status was 
made at study entry and twice per week during follow-up 
with a rapid screening HIV RNA PCR assay followed by a 
con fi rmatory assay (ie, to confi rm an initially positive 
test). Incidence rates are expressed as the number of HIV 
acquisition events per 100 person-years of follow-up.
Statistical analysis
This analysis was done using study records and samples 
from Nov 19, 2012, through to May 31, 2015. Descriptive 
measures were used to summarise the data. Continuous 
variables were summarised using median and 
interquartile range; categorical variables were 
summarised using frequency and percentage. Wilcoxon 
rank sum was used to compare continuous variables and 
Fisher’s exact test was used to compare categorical 
variables between groups. The HIV positivity (time to 
HIV-1 infection) data were analysed with the Kaplan-
Meier method and the signifi cance was tested by log-
rank tests. Cox’s proportional hazards models were used 
to estimate hazard ratios (HRs) and their cor responding 
95% CI. Two-sided p values are reported for all the 
statistical tests used in the analysis and p=0·05 was used 
as the cutoff  for signifi cance. R version 3.1.0 and Prism 
version 6 were used for the statistical analysis.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had fi nal 
responsibility for the decision to submit for publication.
Results
Between Nov 19, 2012, to May 31, 2015, we characterised 
432 HIV-uninfected South African women from the 
FRESH study. In this cohort, 152 (35%) women used an 
injectable progestin-only contraceptive (DMPA or 
NET-EN), 43 women used another form of contraception, 
15 women switched contraceptive methods during the 
study and were not included in the analyses comparing 
injectable progestin-only contraception users to women 
using no  long-term contraception, and 222 (51%) women 
used no method of long-term contraception. Of the 
women using an injectable progestin-only contraceptive, 
116 (76%) used DMPA and the remaining 36 (24%) used 
NET-EN. Use of injectable progestin-only con traceptives 
was self-reported but verifi ed by measuring plasma 
progesterone and oestradiol con centrations in a 
randomly selected subset of 222 women and by directly 
measuring plasma medroxy progesterone acetate 
concentrations in a subset of 44 self-reported DMPA 
users (appendix). There was 97% and 93% concordance 
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between reported DMPA use and measured use by 
progesterone and medroxy progesterone acetate 
quantifi cation, respectively. Of the women who were 
using no long-term contraceptive, 129 were sampled 
during the follicular phase and 77 were sampled during 
the luteal phase, as determined by plasma progesterone 
concentration; the other 16 women were inconclusive 
based on progesterone measurements.
Despite the narrow age range and residency require-
ment dictated by study enrolment criteria, a few small 
demographic diff erences remained between women 
using injectable progestin-only contraceptives and 
women using no long-term contraceptive. Injectable 
progestin-only contraceptive users were 1 year older on 
average (p=0·022) and the age diff erence between the 
participant and her current sexual partner was 1 year 
greater for injectable progestin-only contraceptive users 
than for those using no long-term contraception 
(p=0·00036; table). No diff erences were seen in condom 
use, anal sex frequency, casual partner count, or 
bacterial vaginosis frequency. Injectable progestin-only 
contraceptive use was not associated with increased 
likelihood of having any sexually transmitted infections 
(table).
Despite intensive counselling and education, the HIV 
incidence in the cohort was 7·43 per 100 person-years 
Overall participants* Participants receiving 
DMPA or NET-EN*
Participants receiving no 
long-term contraception* 
Other forms of 
contraception
p value of injectable 
progestin-only contraceptives 
vs no long-term contraception*
Sexual demographics
Median age at enrolment 21 (20–22) 22 (20–23) 21 (20–22) 21 (21–22) 0·02235
Median age diff erence between participant and 
current sexual partner
3 (1–5) 4 (2–6) 3 (1–4) 4 (1–6) 0·00036
Sexual behaviour†
Condom use in past 30 days 0·1539
Always 61/419 (15%) 18/141 (12%) 38/212 (18%) 4/43 (9%) ··
Sometimes 141/419 (34%) 52/141 (35%) 65/212 (31%) 16/43 (37%) ··
Never 102/419 (24%) 41/141 (28%) 44/212 (21%) 16/43 (37%) ··
Not applicable (no sex) 115/419 (27%) 38/141 (25%) 65/212 (30%) 7/43 (16%) ··
Vaginal sex in past 7 days 0·2504
0 times 240/421 (57%) 80/151 (53%) 132/214 (62%) 20/41 (49%) ··
1 time 128/421 (30%) 50/151 (33%) 57/214 (26%) 18/41 (44%) ··
2 or more times 53/421 (12%) 21/151 (14%) 25/214 (12%) 3/41 (7%) ··
Vaginal sex episodes in past 30 days 0·5212
0 times 115/420 (27%) 38/151 (25%) 65/213 (31%) 7/41 (17%) ··
1–5 times 278/420 (66%) 104/151 (69%) 135/213 (63%) 30/41 (73%) ··
More than 5 times 27/420 (6%) 9/151 (6%) 13/213 (6%) 4/41 (10%)
Vaginal drying agent usage 0·4194
Always 5/385 (1%) 2/142 (1%) 1/190 (<1%) 2/40 (5%) ··
Sometimes 50/385 (13%) 20/142 (14%) 20/190 (11%) 8/40 (20% ) ··
Never 330/385 (86%) 120/142 (85%) 169/190 (89%) 30/40 (75%) ··
Anal sex in past 30 days 6/417 (1%) 1/151 (<1%) 5/210 (2%) 0/41 0·2077
Casual or new sex partner in past 30 days 28/419 (7%) 7/151 (5%) 14/212 (7%) 5/41 (12%) 0·4286
Sexual health
Neisseria gonorrhoeae infection 24/394 (6%) 8/151 (5%) 12/190 (6%) 4/40 (10%) 0·8179
Chlamydia trachomatis infection 53/394 (13%) 13/151 (9%) 29/190 (15%) 7/40 (17%) 0·0695
Mycoplasma genitalium infection 30/394 (8%) 8/151 (5%) 17/190 (9%) 5/40 (13%) 0·2170
Trichomonas vaginalis infection 34/394 (11%) 12/151 (8%) 12/190 (6%) 9/40 (22%) 0·6709
HSV-1 infection 4/394 (1%) 2/151 (1%) 2/190 (<1%) 0/40 1·0000
HSV-2 infection 12/394 (3%) 6/151 (4%) 5/190 (3%) 1/40 (3%) 0·5468
Bacterial vaginosis infection (Nugent score ≥7) 102/394 (26%) 33/151 (22%) 54/190 (28%) 12/40 (30%) 0·1719
Data are median (IQR) or n/N (%), unless otherwise specifi ed. p values are determined by Fisher’s exact test for categorical data and by Mann-Whitney for continuous data. These results represent the data collected at 
the most recent visit at which mucosal samples were collected, except when a woman became HIV positive before data was collected, in which case data is from the fi rst HIV-positive visit (within a week of becoming 
infected). Age, age of sexual debut, and age of fi rst partner were collected at the initial study visit. DMPA= Depot medroxyprogesterone acetate. *15 participants switched contraceptive during the study so were not 
included in columns where participants were analysed by contraceptive method. †Sexual behaviour information from one participant using NET-EN and ten participants using no long-term contraception was not 
available.
Table: Baseline characteristics
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(95% CI 4·59–11·36), with 24 women becoming infected 
by the time of analysis. In our study, the HIV incidence in 
injectable progestin-only contraceptive users (12·06 per 
100 person-years, 6·41–20·63) was signifi cantly higher 
than women using no long-term contraception (3·71 per 
100 person-years, 1·36–8·07; HR 3·46, 95% CI 1·37–8·71, 
p=0·0084; fi gure 1, appendix). Demographic and 
behavioural diff erences between injectable progestin-only 
contraceptive users and non-users could not explain this 
increased risk; injectable progestin-only contraceptive use 
remained a signifi cant predictor of HIV acquisition even 
after including the age diff erence between the participant 
and the partner as a covariate in a Cox proportional 
hazards model (adjusted hazard ratio [aHR] 2·93, 95% CI 
1·09–7·86, p=0·0326).
Having established the association between injectable 
progestin-only contraceptive use and HIV acquisition in 
this cohort, we hypothesised that biological correlates of 
injectable progestin-only contraceptive use could help to 
explain this epidemiological association. Hormonal 
contraceptive use has been shown to be associated with 
specifi c genital infl ammatory cytokines18 and a lower 
prevalence of bacterial vaginosis,19 both of which might 
aff ect HIV acquisition risk.
After controlling for low progesterone and adjusting 
for multiple comparisons, no signifi cant diff erences 
were identifi ed in cytokine concentration in injectable 
































Figure 1: Time to infection stratifi ed by contraceptive usage
Kaplan-Meier curve assessing HIV acquisition in women using injectable 
progestin-only contraceptives compared with those on no long-term 
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Figure 2: HIV target cells in women using no LTC compared with women using an IPC
CCR5+ CD4 T cells as a percentage of live CD45+ cells in the blood and cervix (A) and CCR5+ expression as a percentage of CD4 T cells in the blood and cervix (B). CCR5 
expression levels on CD4 T cells as shown by a representative fl uorescence-activated cell sorting histogram (C) and within all patients analysed (D). All participants 
had a plasma progesterone concentration of 0·3 ng/mL or less. p values were determined by the Mann-Whitney test. LTC=long-term contraception. IPC=injectable 
progestin-only contraception. FMO=Fluorescence minus one. MFI=Median fl uorescence intensity.
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progestin-only contraceptive users compared with those 
with no long-term contraception, by contrast with 
previous reports15 (appendix). In view of reports13 
implicating the genital microbiome in infl ammation and 
HIV acquisition risk, we also did bacterial 16S rRNA 
gene sequencing of nucleic acid isolated from cervical 
swabs. We identifi ed no correlation between injectable 
progestin-only contraceptive use and bacterial populations 
in the female genital tract (appendix).
We identifi ed signifi cantly higher frequencies of HIV 
target cells (CCR5+ CD4 T cells) as a percentage of live 
CD45+ cells in the female genital tract of women using 
injectable progestin-only contraceptive compared with 
those using no long-term contraception (3·92 times 
higher, p=0·0241). We did not fi nd this diff erence in 
peripheral blood cells in the same individuals (fi gure 2). 
We identifi ed no diff erence in the number of live cervical 
CD45+ cells in the two groups. Cervical CD4 T cells of 
injectable progestin-only contraceptive users had higher 
CCR5 expression on the cell surface, as measured by the 
proportion of CD4 T cells expressing CCR5 (1·32 times 
higher, p=0·0048; fi gure 2), and higher median 
fl uorescent intensity of CCR5 staining (p=0·0157; 
fi gure 2). Analysis of peripheral blood CD4 T cells in the 
same individuals did not show diff erences (fi gure 2). 
Oestradiol concentration did not correlate with CCR5+ 
CD4 T cell frequency or CCR5 expression (appendix).
Because activated target cells produce more viral 
particles per cell than resting target cells,20,21 which might 
accelerate viral dissemination,22 we next assessed target 
cell activation using the cell surface markers IL2Rα chain 
(CD25), HLA-DR, and CD38. Women using injectable 
progestin-only contraceptives had no diff erence in 
CD25+ target cells in the blood (fi gure 3) but had a 
signifi cantly higher frequency of these cells in the female 
genital tract (p=0·0193; fi gure 3). Cervical target cells 
from injectable progestin-only contraceptive users did 
not co-express HLA-DR and CD38 at higher levels 
(appendix). Thus, injectable progestin-only contraceptive 
users had not only a higher frequency of cervical target 
cells but also more activated CD25+ target cells.
In view of the increased HIV target cells seen with 
exogenous progestin administration, we next examined 
whether natural states of high progestin, occurring 
during the luteal phase of the menstrual cycle, also 
exhibit female genital tract-specifi c changes in HIV 
target cells. Women in the luteal phase had a higher 
cervical target cell frequency (3·25 times higher, 
p=0·0488; fi gure 4) and more CCR5 expressing 
CD4 T cells (1·10 times higher, p=0·0433; fi gure 4) than 
women in the follicular phase.
Discussion
Defi ning the role of injectable progestin-only 
con traceptives in HIV acquisition is of utmost relevance, 
particularly in regions of the world where HIV trans-
mission is highest. By prospectively following 
HIV-negative women in an area of high incidence, we 
fi rst establish that injectable progestin-only contraceptives 
users in this cohort had signifi cantly increased rates of 
HIV acquisition, an observation that has been shown 
previously in many2–4 but not all23,24 large cohorts. More 
importantly, we show that injectable progestin-only 
contraceptive use is associated with higher levels of HIV 
target cells in the cervix, providing a biological explanation 
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Figure 3: Frequency of activated HIV target cells in women using no LTC compared with women using an IPC
HIV target cell activation as measured by CD25+CCR5+ CD4 T cells as a percentage of live CD45+ cells in the 
peripheral blood (A) and the cervix (B). All participants had plasma progesterone concentrations of 0·3 ng/mL or 
































Figure 4: Cervical HIV target cell frequency in the follicular and luteal phases of the menstrual cycle
Frequency of cervical CCR5+ CD4 T cells of live CD45+ T cells (A) and CCR5 expression on cervical CD4 T cells (B) in 
women using no long-term contraceptive in the follicular versus luteal phases of the menstrual cycle. The follicular 
phase was defi ned as plasma progesterone concentration of 0·3 ng/mL or less; the luteal phase was defi ned as a 
plasma progesterone concentration of 1·2 ng/mL or above. p values were determined by the Mann-Whitney test.
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show that a high level of endogenous progesterone is 
similarly associated with a higher frequency of cervical 
HIV target cells, supporting the conclusion that this 
cellular pattern is a biological eff ect of a high progestin 
state rather than an artifact of behavioural or demographic 
confounders associated with injectable progestin-only 
contraceptive use. These fi ndings support a role for both 
endogenous and exogenous progestins in modulating the 
frequency of cervical target cells.
Behavioural and demographic confounders have 
previously obscured defi nitive analysis of an association 
between injectable progestin-only contraceptive use and 
HIV acquisition risk.2,6 Because participants were from a 
narrow age range and a single community, our cohort 
allowed pointed assessment of the link between 
injectable progestin-only contraceptive use and HIV 
acquisition. Of the potential confounders that we 
assessed, only age and age diff erence between a woman 
and her partner were signifi cantly diff erent between 
groups. These diff erences, although statistically signi-
fi cant, were very small in magnitude and of uncertain 
biological signifi cance. In a Cox proportional hazard 
model, injectable progestin-only contraceptive use 
remained a signifi cant predictor of HIV acquisition.
Previous epidemiological studies6 concluding that 
hormonal contraceptives increase risk have been faulted 
for a lack of coordinated investigation of plausible 
biological causes. We pursued the hypothesis that 
biological factors explain the increased HIV incidence in 
injectable progestin-only contraceptive users. In-vitro 
studies7–10 of human cells and tissue have suggested that 
endogenous reproductive hormones and exogenous 
progestins might directly aff ect immune cell function. 
Potential in-vivo eff ects have been less well described. We 
therefore assessed the immunological environment of 
the female genital tract in injectable progestin-only 
contraceptive users in our cohort, with particular focus 
on the frequency of HIV target cells at the site of exposure 
as a potential explanation for increased HIV acquisition.7,22 
Women using injectable progestin-only contraceptives 
had a signifi cantly higher frequency of activated cervical 
CCR5+ CD4 T cells. Activated target cells are not only 
more prone to infection but also support higher degrees 
of viral replication than resting cells.20,21 The increased 
frequency of activated cervical target cells therefore likely 
accelerates viral dissemination after exposure to HIV in 
the female genital tract.
Although the use of injectable progestin-only 
con traceptives has been of particular interest with respect 
to increased HIV acquisition risk, the luteal phase of the 
menstrual cycle, characterised by high endogenous 
progesterone, has also been described through model 
systems as a time of increased risk of HIV acquisition.25,26 
We therefore examined cervical immune cells in women 
in diff erent stages of the menstrual cycle. With the use of 
plasma progesterone concentrations to defi ne follicular 
and luteal phases, we identifi ed signifi cantly higher HIV 
target cell frequency in the luteal phase. We conclude 
that women in any high progestin state—because of 
injectable progestin-only contraceptive use or naturally 
high endogenous progesterone—had increased HIV 
target cell frequency in the cervix compared with women 
in a low progestin state. No diff erence was reported in 
cervical target cell frequency between high progestin 
states (DMPA use, NET-EN use, and naturally high 
endogenous progesterone), suggesting a common 
immunomodulatory eff ect.
Our study had several limitations. The sample size was 
much smaller than previously published epidemiological 
studies examining the link between injectable progestin-
only contraceptive use and HIV acquisition, which 
limited our ability to investigate the potential diff erential 
eff ects of DMPA and NET-EN use. Also, our analysis of 
immunological changes in the cervix during the follicular 
and luteal phase would have ideally been done by high 
frequency longitudinal sampling.
By showing the eff ect of injectable progestin-only 
contraceptives on HIV target cells in vivo, we provide a 
plausible biological mechanism for the signifi cantly 
increased risk of HIV acquisition in women using 
injectable progestin-only contraceptives. We also noted 
similar immunological changes in the female genital 
tract of women in naturally high progestin states, which 
suggests that increased HIV acquisition risk is likely 
driven by both exogenous and endogenous progestin 
exposure. The signifi cance of this analysis is two-fold. 
First, our fi ndings in naturally cycling women further 
support that notion that diff erences in cellular 
phenotype and frequency are due to a biological eff ect, 
rather than to behavioural or demographic confounding. 
Second, if the target cell eff ect is truly mediated by both 
exogenous and endogenous progestins, then increased 
HIV acquisition risk might aff ect not only women using 
injectable progestin-only contraceptives but also 
naturally cycling women in the luteal phase. We also 
importantly identifi ed that injectable progestin-only 
contraceptive use was not associated with increased 
genital infl am mation or changes in bacterial 
communities, both of which have been associated with 
increased HIV acquisition in women, which suggests 
that the mecha nism of increased HIV risk mediated by 
injectable progestin-only contraceptive is distinct from 
that of these other biological mediators, although these 
risk factors might converge on a common pathway of 
inducing increased HIV target cells in the female 
genital tract.
Our results suggest that a specifi c biological 
mecha nism underlies the association between progestin 
exposure, particularly in the form of injectable progestin-
only contraceptive use, and increased HIV acquisition 
risk in women. The eff ect of these fi ndings on recom-
mendations for women living in regions with high HIV 
incidence remains unclear. The potential risks of 
injectable progestin-only contraceptives will need to be 
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weighed against those of other contraceptive alternatives 
and communicated clearly to women facing these 
choices. Together, our fi ndings show new mechanistic 
insight into the role of progestins in HIV acquisition risk 
and suggest that eff orts aimed at decreasing genital 
target cell availability in high progestin states might aid 
in the development of prophylactic strategies to improve 
prevention of HIV infection in women.
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